Chiral Furans

Gold(III) Chloride Catalyzed Synthesis of Chiral Substituted 3-Formyl Furans from Carbohydrates: Application in the Synthesis of 1,5-Dicarbonyl Derivatives and Furo[3,2-c]pyridine

Kanchan Mal, Abhinandan Sharma, and Indrajit Das*^[a]

Abstract: This report describes a gold(III)-catalyzed efficient general route to densely substituted chiral 3-formyl furans under extremely mild conditions from suitably protected 5-(1-alkynyl)-2,3-dihydropyran-4-one using H₂O as a nucleophile. The reaction proceeds through the initial formation of an activated alkyne–gold(III) complex intermediate, followed by either a domino nucleophilic attack/*anti-endo-dig* cyclization, or the formation of a cyclic oxonium ion with subsequent attack by H₂O. To confirm the proposed mechanistic pathway, we employed MeOH as a nucleophile instead of H₂O to result in a substituted furo[3,2-*c*]pyran derivative, as anticipated. The similar furo[3,2-*c*]pyran skeleton with

Introduction

Diversely substituted furans form an important structural motif prevalent in a biologically indispensable natural products, several pharmaceuticals, agrochemicals, as well as flavoring and aroma compounds.^[1] They are also useful building blocks found in synthetic organic chemistry, materials chemistry, and self-healing macromolecular materials.^[2] Moreover, the functionalized furan core has attracted tremendous attention for the design of numerous intermediates and as versatile starting materials for the synthesis of heterocyclic as well as acyclic compounds.^[2a, 3] Importantly, substituted chiral furans find widespread applications as versatile synthetic intermediates and are commonly found in many bioactive natural products (Figure 1).^[2f,4]

Despite the development of numerous methods for the synthesis of highly substituted furans in the past few years, including transition-metal-mediated cyclization and cycloisomerization methods,^[2-5] devising efficient access to substituted chiral furans from common precursors remains a challenging task. Among the many methods developed so far, the reaction of

[a] K. Mal, A. Sharma, Dr. I. Das Chemistry Division
CSIR-Indian Institute of Chemical Biology
4, Raja S. C. Mullick Road Jadavpur, Kolkata 700032 (India)
Fax: (+91) 33-2473-5197
E-mail: id@csiriicb.in

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/chem.201402286. a hybrid carbohydrate–furan derivative has also been achieved through pyridinium dichromate (PDC) oxidation of a substituted chiral 3-formyl furan. The corresponding protected 5-(1-alkynyl)-2,3-dihydropyran-4-one can be synthesized from the monosaccharides (both hexoses and pentose) following oxidation, iodination, and Sonogashira coupling sequences. Furthermore, to demonstrate the potentiality of chiral 3-formyl furan derivatives, a TiBr₄-catalyzed reaction of these derivatives has been shown to offer efficient access to 1,5-dicarbonyl compounds, which on treatment with NH₄OAc in slightly acidic conditions afforded substituted furo[3,2-c]pyridine.

metalated furans with the carbonyl group or various other electrophiles,^[6] a Grignard-type addition reaction of furan carbaldehyde with a variety of nucleophiles,^[7] and Lewis acid catalyzed Friedel–Crafts-type reactions of various carbonyl compounds with furan derivatives are more common.^[8] Chiral products may be accessed by the use of chiral pool precursors such as carbohydrates,^[9] by enzymatic resolution of racemic mixtures,^[10] or by kinetic resolution of starting materials.^[11] In addition to the Garcia Gonzalez reaction,^[12] addition/oxidative rearrangement of 3-furfurals with *N*-bromosuccinimide (NBS)^[13] and tandem Suzuki–Miyaura coupling followed by acid-catalyzed cyclization^[14] also offer new ways to obtain polyhydroxylated furans.

Furthermore, substituted 3-formyl furan derivatives have found widespread applications as synthetic intermediates for the synthesis of bioactive natural products.^[15] However, there is a lack of general methods to synthesize them;^[16] the few methods available mainly involve the metalation of furan rings



Figure 1. Examples of bioactive chiral furan-containing natural products.

Chem. Eur. J. 2014, 20, 1-15

Wiley Online Library

These are not the final page numbers! 77

1



followed by formylation.^[6b, 17] This approach is somewhat restricted, because after metalation the addition of electrophiles to furan rings occurs preferentially at the C-2 and C-5 positions, and there is always a great deal of difficulty separating them from the unwanted regioisomers. The corresponding chiral products are also potentially important synthetic intermediates; however, their utility is very much underexplored owing to the lack of general methods to synthesize them.^[13] As a consequence, establishing more efficient routes to highly substituted chiral 3-formyl furans from easily accessible starting materials continues to captivate synthetic chemists.

Herein, we report a gold(III)-catalyzed efficient route to highly substituted chiral 3-formyl furans under extremely mild conditions using H₂O as a nucleophile from a suitably protected 5-(1-alkynyl)-2,3-dihydropyran-4-one. The latter can be prepared from the corresponding appropriately functionalized monosaccharides or commercially available glycals in a few steps following oxidation, iodination, and Sonogashira coupling sequences. To confirm the proposed mechanistic pathway in the gold-catalyzed reaction, we employ MeOH as a nucleophile instead of H₂O to result in a substituted furo[3,2c]pyran derivative. The synthesis of a similar skeleton with a hybrid carbohydrate-furan derivative was also carried out with pyridinium dichromate (PDC) oxidation of chiral 3-formyl furan. Furthermore, the substituted 3-formyl furans could then be smoothly subjected to a TiBr₄-catalyzed process to produce 1,5-dicarbonyl compounds, which on treatment with NH₄OAc under slightly acidic conditions afforded furo[3,2-c]pyridine.

Results and Discussion

A detailed retrosynthetic strategy towards substituted chiral furans from suitably substituted 2-iodoglycals as starting material is depicted in Scheme 1. 2-lodoglycals (**2**) can easily be synthesized from the corresponding appropriately functionalized monosaccharides or commercially available glycals in a few



Scheme 1. Retrosynthetic analysis and synthetic applications of polyhydroxylated chiral substituted 3-formyl furans from monosaccharides (both hexoses and pentoses). PG = protecting group.

Chem. Eur. J. 2014, 20, 1–15 www.chemeurj.org

steps by following a well-documented literature procedure (see the Supporting Information for details).^[18] To obtain the carbohydrate congeners, we used different hexoses such as Dglucose, D-galactose, L-rhamnose, and L-fucose as well as the pentose sugar D-xylose.^[18,19] Common protecting groups such as –COCH₃ (acetyl), –CH₂Ph (benzyl), and –TBDMS (*tert*-butyldimethylsilyl) were used for hydroxyl-group protection in monosaccharides. 2-Alkynylated sugars (**3** a–**p**) were synthesized by the [Pd(PPh₃)₂Cl₂]/Cul-catalyzed standard Sonogashira coupling reaction (Scheme 2).^[16c,20]



Scheme 2. Synthesis of 5-(1-alkynyl)-2,3-dihydropyran-4-ones from substituted 2-iodoglycals by Sonogashira coupling.

We used a variety of different aromatic, aliphatic, and TMSprotected commercially available terminal alkynes as coupling partners. It was found that the alkynes with electron-neutral (3a-e) or electron-donating substituents (3f-j) on the aromatic ring resulted in 2-alkynylated carbohydrates in good to excellent yields (57–90%; Scheme 2). However, the yields were moderate (40–58%; Scheme 2) when substrates with electronwithdrawing substituents (3k-n) on the aromatic ring were employed.

Importantly, trimethylsilyl acetylene was also found to be amenable to the reaction conditions that afforded the corresponding 2-alkynylated products (**3o**-**p**, Scheme 2) in greater than 70% yields. However, the coupling reaction with alkylace-

© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

R These are not the final page numbers!

2



CHEMISTRY A European Journal Full Paper

tylene did not produce the desired product by following the general procedure (Scheme 2). After several attempts, the coupling reaction with alkylacetylenes was successfully achieved with $[Pd(PPh_3)_2Cl_2]/Cul/Et_3N$ in moderate yields (**3 q-s**, 52–56%; Scheme 2) by following the literature procedure.^[20b,c]

During our initial investigations, we occasionally found that a solution of 3a in EtOAc showed a marked propensity to undergo cyclization upon exposure to open air to result in 4a in 50% yield after 48 h. A systematic study of this transformation (to shorten the time period and to achieve higher yields) showed that treating 3a in THF with H₂O (0.2 mL) as a nucleophile at room temperature furnished 4a in 55% yield (Table 1, entry 1). Interestingly, treatment with Brønsted acids such as methanesulfonic acid (MeSO₃H), HCl, and HBr failed to improve the yield (32-51%) even after 12-26 h (Table 1, entries 2-4). Other metal catalysts such as Cul, CuBr, AqNO₃, PPh₃AuCl, and AuCl also catalyzed this transformation, but resulted in moderate to lower yields (Table 1, entries 5-9). However, the more reactive cationic Au¹ catalysts Ph₃PAuNTf₂ and PPh₃AuCl+AgOTf (10 mol%) accelerated the transformations with excellent yields, and the reaction proceeded to completion within 10 to 15 min (Table 1, entries 10 and 13; 90%); whereas 1 mol% of Ph₃PAuNTf₂ also catalyzed this transformation, but it was nec-

Table 1. Reaction optimization for substituted chiral 3-formyl furans from3-benzyloxy-2-benzyloxymethyl-5-phenylethynyl-2,3-dihydropyran-4-one. ^[a]				
-	BnO BnO 3a	H₂O atalyst, THF, RT	OH OBn OBn 4	Ph la
Entry	Catalyst	MOI [%]	t	field [®] [%]
1	no catalyst	-	48 h	55
2	MeSO₃H	20	12 h	32
3	HCI	10	24 h	51
4	HBr/AcOH	10	26 h	50
5	Cul	10	12 h	52
6 ^[c]	CuBr	10	10 h	42
7	AgNO₃	10	12 h	73
8	PPh ₃ AuCl	10	12 h	65
9	AuCl	10	10 min	71
10	PPh ₃ AuNTf ₂	10	10 min	90
11	PPh ₃ AuNTf ₂	1	20 h	89
12	$PPh_{3}AuCI + AgBF_{4}$	10	15 h	87
13	PPh ₃ AuCl+AgOTf	10	15 min	90
14	AuCl ₃	1	5 h	91
15	AuCl ₃	0.7	18 h	90
16	AuCl ₃	0.5	26 h	90
17	AuCl ₃	5	10 min	92
18	AuCl	10	10 min	96
19	AuBr ₃	10	10 min	90
20 ^[d]	AuCl ₃	10	10 min	42
21 ^[e]	AuCl ₃	10	10 min	77
[a] By stirring a mixture of 3a (0.03 g, 0.071 mmol, 1.0 equiv) and catalyst (mol%) in dry THF (2 mL) under an Ar atmosphere at room temperature				

(mol%) in dry THF (2 mL) under an Ar atmosphere at room temperature (20–25 °C), employing time as noted, followed by quenching with H₂O. [b] Yields are of isolated products. [c] Reaction was performed at 50 °C. [d] Reaction was carried out in acetonitrile. [e] Reaction was carried out in dichloromethane; Tf = trifluoromethane sulfonyl.

These are not the final page numbers! 77

essary to conduct the reaction for a longer reaction time (Table 1, entry 11; 20 h, 89%). Inspired by these cationic Au¹ catalyst results, we also explored the scope of this cyclization reaction with Ph₃PAuCl+AgBF₄. We observed that 10 mol% of this catalyst was not as effective as other gold(I) catalysts (Table 1, entry 12; 87%). Interestingly, a catalytic amount of AuCl₃ (0.5, 0.7, and 1 mol%) was also found to be equally effective (Table 1, entries 14-16; 90-91% yield), but once again longer reaction times were necessary. The use of 5 mol % AuCl₃ accelerated the transformation (Table 1, entry 17), and the reaction proceeded to completion within 10 min (Table 1). The yield was improved further with 10 mol% of AuCl₃ (Table 1, entry 18; 96% yield). AuBr₃ was also found to be almost equally effective (Table 1, entry 19). However, the use of other solvents (CH₃CN and CH₂Cl₂) failed to improve the yield (Table 1, entries 20 and 21). Thus, we concluded that the use of 10 mol% AuCl₃ in THF at room temperature constitutes the optimized reaction conditions.

Having established the optimized protocol, we next investigated the substrate scope and generality for this transformation with H₂O as a nucleophile. Scheme 3 summarizes the results. In general, the reaction is tolerant to variation in substitution/protection at both the alkyne and the 4- and 6-positions of the hexopyranose ring. It is interesting to note that the electronic nature of the aromatic substituents on the alkyne moiety and the substitution/protection in carbohydrate congeners played a significant role in the yield of the reaction. With benzyl as a protecting group for the hexopyranose OH groups, substrates that contain electron-neutral (4a, b, d, e) or electrondonating (4 f, g, i, j) substituents on the terminal alkyne resulted in chiral substituted 3-formyl furans in moderate to excellent yields (Scheme 3; 43-96%). However, substrates that contain electron-withdrawing substituents delivered the corresponding chiral furans (4k, l, n) only in moderate yields (Scheme 3; 42-67%). Furthermore, replacement of the aryl group with an alkyl group in the terminal alkyne was also found to be compatible under the reaction conditions and delivered the corresponding chiral furans (4q-s) in moderate to good yields (Scheme 3; 52-82%).

When we replaced the benzyl protection for OH groups with a TBDMS group, it lowered the yield dramatically (**4c**, **h**, **m**, Scheme 3; 21–49%). This might be attributed to the acid hydrolysis of the primary TBDMS group during the course of the reaction, which results from the mild acidic property of AuCl₃ in H₂O, as it is well-documented in the literature that a secondary benzylic hydroxyl group protected by TBDMS substitution is stable under gold catalysis.^[21] However, the purported products remained to be isolated by silica-gel column chromatography. Thus, the possibility of competing intermolecular Reppetype vinylation that results from the C-4 hydroxyl group of the hexopyranose ring might play an important role in the low yields with the TBDMS group.^[21b,22a]

To achieve higher yields for the entries with lower than 50% yields (Scheme 3), the more reactive cationic gold(I) catalyst was examined.^[22b,c] To our surprise, when we treated **3c** with Ph₃PAuNTf₂ (10 mol%)/THF/H₂O at room temperature, the corresponding **4c** was isolated in 81% yield, and the reaction pro-

Chem. Eur. J. 2014, 20, 1-15

www.chemeurj.org



Scheme 3. $AuCl_{3}$ - and $Ph_{3}PAuNTf_{2}$ -catalyzed synthesis of substituted chiral 3-formyl furans from protected 5-(1-alkynyl)-2,3-dihydropyran-4-ones.

ceeded to completion within 20 min. However, we observed that use of 0.5 mol% $Ph_3PAuNTf_2$ was not effective to catalyze this transformation (46% yields), even after 44 h. Similarly, under these remarkably mild reaction conditions, the other 2-alknylated glycals (**3d** and **3h**) were converted to their respective furans (**4d** and **4h**) in moderate to good yields relative to the AuCl₃-catalyzed reaction (Scheme 3). Unfortunately, **3k** and **3m** did not produce the corresponding **4k** and **4m** in satisfactory yields under the same conditions, ostensibly owing to the presence of a strong electron-withdrawing ($-NO_2$) group on the aromatic ring (Scheme 3).

All the above reactions in Scheme 3 proceeded to full conversion to the product irrespective of the starting materials used, as monitored by TLC. For some of the entries, the drop in yield was due to the inherent reactivity of these systems as well as degradation of some of the products during column chromatography (with both silica gel and neutral or basic alumina). Otherwise, most of the substituted chiral furan aldehydes were stable, and we did not find any difficulty in purifiCHEMISTRY A European Journal Full Paper

cation or storing them for a long time. The structures of 3formyl furan products were assigned by 2D NMR spectroscopy (see the Supporting Information).

The probable mechanism of the reaction may be explained on the basis of that proposed for the chromones system.^[23] After the initial formation of an activated alkyne–gold intermediate in the presence of AuCl₃, it would undergo either a domino nucleophilic attack by H₂O followed by *anti-endo-dig* cyclization (Scheme 4, path A) or the formation of a cyclic oxonium ion with subsequent attack by H₂O (Scheme 4, path B).



Scheme 4. A plausible mechanism for the formation of chiral substituted furan.

Inspired by the above findings, and to further exploit the potential of AuCl₃ as a catalyst for chiral substituted furan synthesis, the TMS-protected 2-alkynylated glycal derivatives (**3o** and **3p**) were treated under the standard reaction conditions.^[23a] The results are shown in Scheme 5. To our delight, **3o** also underwent AuCl₃-catalyzed cyclization, and the corresponding furan derivative **4o** was obtained in only 9% yield. In addition, products **4oa** and **4ob** were also isolated in 11 and 16% yields, respectively (Scheme 5). Formation of **4ob** could be explained on the basis of removal of the TMS group either prior to or soon after cyclization under slightly acidic reaction conditions (AuCl₃/H₂O), whereas **4oa** resulted from a 1,2-Si migration from C-5 to the carbenoid center generated at C-4.

This unique 1,2-Si migration is particularly attractive as it allows the synthesis of hitherto inaccessible unsymmetrical 2,3disubstituted C-4 silylated chiral furans.^[16a] Further work is in progress to increase the yield of the desired product. A perusal of the literature also revealed that the 1,2-Si migration is kinetically favored over 1,2-H migration in the case of an Au–carbene intermediate.^[2a,24] Switching to the galacto substrate **3p** also revealed the same situation (furan derivative **4p**, 35%,

Chem. Eur. J. 2014, 20, 1 – 15 www.ch

www.chemeurj.org

4



Scheme 5. Scope for the gold-catalyzed synthesis of polyhydroxylated chiral furans from TMS-protected 2-alkynylated glycals.

and desilylated product **4pb**, 30%), except that the 1,2-Si migration product **4pa** was isolated only in trace amount (Scheme 5). To achieve higher yields for the unsymmetrical 2,3disubstituted C-4 silylated chiral furans, the more reactive cationic gold(I) catalysts were examined. To our great disappointment, when we treated **3p** with 10 mol% Ph₃PAuNTf₂ and PPh₃AuCl + AgOTf, respectively, only the corresponding **4pb** (Scheme 5; 30–32%) was isolated, devoid of any **4p** and **4pa**. In addition, product **4pc**, which resulted from the desilylation of **3p** before cyclization, was also obtained in 34 and 18% yields, respectively (see the Supporting Information). Subsequently, we successfully performed the PPh₃AuNTf₂-catalyzed cyclization reaction of **4pc** to yield **4pb** (Scheme 5; 48%).

Interestingly, when MeOH was used as a nucleophile instead of H₂O in the AuCl₃-catalyzed cyclization, the corresponding substituted 4-methoxy-2-phenyl-6,7-dihydro-4*H*-furo[3,2c]pyran **5a** was isolated from **3c** in moderate yield (Scheme 6; 55%),^[25] which might be considered a hybrid carbohydratefuran derivative, and also confirmed the mechanistic pathway described in Scheme 4. The stereochemistry of MeOH addition was assigned on the basis of NOESY experiments (see the Supporting Information). Furthermore, synthesis of substituted



Scheme 6. Synthesis of substituted furo[3,2-c]pyran derivatives.

Chem. Eur. J. 2014, 20, 1 – 15 www.

www.chemeurj.org

These are not the final page numbers! 77

furo[3,2-c]pyran-4-one (**5 b**) could be possible upon PDC oxidation of chiral substituted furan **4a** (Scheme 6; 40%).^[26]

To demonstrate the potential utility of the highly substituted polyhydroxylated furan derivatives, we undertook a synthesis of 2-phenyl-substituted furo[3,2-*c*]pyridine. Substituted furo[3,2-*c*]pyridines form a key structural unit in drugs and biologically active natural products and exhibit a wide range of pharmaceutical activities.^[27] Owing to their potential applications, a number of synthetically useful routes have been developed for their synthesis.^[28] Furthermore, a literature survey revealed that treatment of α , β -unsaturated 1,5-dicarbonyl derivatives with NH₄OAc under mild acidic conditions delivered the corresponding substituted pyridine in good to excellent yield.^[29]

We therefore became interested in the synthesis of the key intermediate α , β -unsaturated 1,5-dicarbonyl derivatives from our synthesized furan products. When we treated **4a** or **4b** with TiBr₄ (2 equiv) in toluene under reflux conditions, the corresponding 1,5-dicarbonyl derivative **6** was isolated in 43% yield (Scheme 7).



Scheme 7. Synthesis of substituted 2-phenylfuro[3,2-*c*]pyridine through 1,5-dicarbonyl derivative.

The mechanism of the reaction might be explained on the basis of generation of the oxonium cationic species (II) through TiBr₄-mediated formation of complex (I) with secondary –OBn group, as described in Scheme 7.^[30] Rearomatization of the furanoid ring and subsequent tautomerization afforded α , β -unsaturated 1,5-dicarbonyl derivative **6**. With the α , β -unsaturated 1,5-dicarbonyl derivative **6**. With the α , β -unsaturated 1,5-dicarbonyl precursor in hand, we next turned our attention to the synthesis of substituted furo[3,2-*c*]pyridine following the literature procedure.^[29] The treatment of **6** with EtOH/NH₄OAc under mild acidic conditions at 40 °C indeed delivered the corresponding 2-phenyl-substituted furo[3,2-*c*]pyridine **7** in 60% yield (Scheme 7).

Conclusion

In conclusion, we have successfully developed an efficient general route to densely functionalized chiral 3-formyl furans from suitably protected 5-(1-alkynyl)-2,3-dihydropyran-4-ones using catalytic $AuCl_3$ and water as a nucleophile. The reactions pro-



ceeded under mild conditions and resulted in moderate to excellent yields. The protected 5-(1-alkynyl)-2,3-dihydropyran-4ones have been prepared from the corresponding monosaccharides following oxidation, iodination, and Sonogashira coupling sequences. The potential of this approach has been described by the preparation of a substituted furo[3,2-*c*]pyridine derivative by following two-step reaction sequences: a TiBr₄catalyzed reaction of the 3-formyl furan derivatives resulted in the 1,5-dicarbonyl compound, which on treatment with NH₄OAc under slightly acidic conditions afforded substituted furo[3,2-*c*]pyridine. The scope and limitations of these new densely functionalized chiral furans towards synthesis of biologically active heterocycles are currently under study in our laboratory.

Experimental Section

General information

Melting points were determined in open-end capillary tubes and are uncorrected. TLC was performed on silica gel plates (Merck silica gel 60, f_{254}), and the spots were visualized with UV light (254 and 365 nm) or by charring the plate dipped in 5% H₂SO₄/MeOH or 5% H₂SO₄/vanillin/EtOH solution. ¹H (300 and 600 MHz) and ¹³C (75 and 150 MHz) NMR spectra were recorded in CDCl₃ solvent using TMS as the internal standard. HRMS (*m/z*) was measured using El and ESI techniques. Infrared (IR) spectra were recorded using Fourier transform infrared spectroscopy; only intense peaks are reported. Optical rotations were recorded at 589 nm.

A. General procedure for the synthesis of 3a-p

Corresponding iodo compounds (2a-g, 1.0 equiv) in dry THF (10 mLmmol⁻¹) were placed separately into a flame-dried, twonecked, round-bottomed flask equipped with a magnetic stir bar and rubber septa. [PdCl₂(PPh₃)₂] (0.05 equiv), terminal alkyne (2.0 equiv), and Cul (0.1 equiv) were added into the flask at 0 $^\circ\text{C}$ and then N,N-diisopropylethylamine (DIPEA; 3.0 equiv) was added dropwise to the resulting mixtures and allowed to stir at room temperature for the required times. After completion of the reaction (TLC), saturated NH₄Cl solution was added, and the product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The crude residue was purified by using silica gel column chromatography (230-400 mesh particle size; eluent: ethyl acetate/n-hexane) to obtain **3**a-p. These compounds should not be either stored in solution or exposed to open air for a long time, as they showed a marked propensity to undergo cyclization to result in mixtures of 3a-p and 4a-p. Owing to this tendency for cyclization, HRMS for some of these derivatives were not matched exactly.

B. General procedure for the synthesis of 3 q-s

Corresponding iodo compounds (**2** a, b, 1.0 equiv) and the respective aliphatic terminal alkyne (2.0 equiv) were dissolved separately in NEt₃ (30 mL mmol⁻¹) in a flame-dried, two-necked, round-bottomed flask equipped with a magnetic stir bar and rubber septa. [PdCl₂(PPh₃)₂] (5 mol%) and Cul (10 mol%) were subsequently added into the flask, and the resulting mixtures were allowed to stir at room temperature for the required times. After completion of the reaction (TLC), saturated NH₄Cl solution was added, and the

product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na_2SO_4 and filtered, and the filtrate was concentrated under reduced pressure to obtain a residue. The crude residue was purified by using silica gel column chromatography (230–400 mesh particle size; eluent: ethyl acetate/*n*-hexane) to obtain **3 q–s**.

3-Benzyloxy-2-benzyloxymethyl-5-phenylethynyl-2,3-dihydropyran-4-one (3 a)

Compound **2a** (0.1 g, 0.222 mmol) was converted to **3a** (0.08 g, 85%) by following general procedure A: eluent, EtOAc/*n*-hexane (8%); $[a]_{D}^{20} = +147$ (c=0.1 in MeOH); yellow gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.74$ (s, 1H), 7.47–7.50 (m, 2H), 7.30–7.38 (m, 13H), 5.08 (d, J=11.1 Hz, 1H), 4.62 (d, J=10.8 Hz, 1H), 4.51–4.64 (m, 3H), 4.29 (d, J=10.8 Hz, 1H), 3.82 ppm (d, J=3.0 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 190.3$, 165.3, 137.3, 137.1, 131.6 (2 CH), 128.5 (4 CH), 128.4 (2 CH), 128.2 (3 CH), 128.1, 127.9, 127.8 (2 CH), 122.9, 103.7, 92.3, 81.6, 79.3, 74.5 (CH₂), 73.7, 73.6 (CH₂), 67.7 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max} = 2217$, 1694, 1604, 1588, 1247, 1149, 1102 cm⁻¹; HRMS (ESI): m/z calcd for C₂₈H₂₄O₄Na [*M*+Na]⁺: 447.1573; found: 447.1943.

3-Benzyloxy-2-benzyloxymethyl-5-phenylethynyl-2,3-dihydropyran-4-one (3 b)

Compound **2b** (0.1 g, 0.222 mmol) was converted to **3b** (0.085 g, 90%) by following general procedure A: eluent, EtOAc/*n*-hexane (10%); $[\alpha]_{20}^{20} = +66$ (c=0.1 in MeOH); yellow gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.79$ (s, 1H), 7.48–7.51 (m, 2H), 7.30–7.37 (m, 13H), 4.75 (d, J=11.7 Hz, 1H), 4.47–4.60 (m, 4H), 3.93 (dd, J=6.9, 10.2 Hz, 1H), 3.82 (d, J=2.1 Hz, 1H), 3.78 ppm (dd, J=5.4, 10.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 186.4$, 165.7, 137.2, 136.6, 131.5 (2CH), 128.4 (2CH), 128.4 (2CH), 128.3 (2CH), 128.2 (2CH), 128.0, 127.9, 127.7 (2CH), 122.9, 103.5, 92.4, 81.1, 79.8, 73.6 (CH₂), 73.4, 72.0 (CH₂), 67.2 ppm (CH₂); IR (neat): $\tilde{\nu}_{max} = 2218$, 1683, 1588, 1367, 1256 cm⁻¹; HRMS (ESI): m/z calcd for C₂₈H₂₄O₄Na [M+Na]⁺: 447.1573; found: 447.3194.

2-(*tert*-Butyldimethylsilanyloxymethyl)-3-hydroxy-5-phenylethynyl-2,3-dihydropyran-4-one (3 c)

Compound **2c** (0.1 g, 0.26 mmol) was converted to **3c** (0.079 g, 85%) by following general procedure A: eluent, EtOAc/*n*-hexane (10%); $[\alpha]_{D}^{20} = +89$ (c=0.1 in MeOH); brown gum. ¹H NMR (600 MHz, CDCl₃): δ =7.68 (s, 1H), 7.44–7.46 (m, 2H), 7.29–7.31 (m, 3H), 4.73–4.76 (m, 1H), 4.61 (d, J=6.6 Hz, 1H), 4.09 (dd, J=3.6, 11.4 Hz, 1H), 3.95 (dd, J=2.4, 11.4 Hz, 1H), 3.66 (brs, 1H), 0.87 (s, 9H), 0.05 ppm (d, J=9.0 Hz, 6H); ¹³C NMR (150 MHz, CDCl₃): δ = 189.6, 165.9, 131.6 (2CH), 128.2 (2CH), 128.2, 123.1, 102.1, 92.0, 82.5, 79.2, 68.5, 61.3 (CH₂), 25.7 (3CH₃), 18.2, -5.7, -5.8 ppm; IR (KBr): \tilde{v}_{max} =2214, 1691, 1602, 1588, 1253, 1140 cm⁻¹; HRMS (ESI): m/z calcd for C₂₀H₂₆O₄SiNa [M+Na]⁺: 381.1498; found: 381.1515.

3-Benzyloxy-2-methyl-5-phenylethynyl-2,3-dihydropyran-4one (3 d)

Compound **2d** (0.1 g, 0.29 mmol) was converted to **3d** (0.077 g, 84%) by following general procedure A: eluent, EtOAc/*n*-hexane (8%); $[\alpha]_D^{20} = -159$ (c = 0.1 in MeOH); brown solid; m.p. 90 °C. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.78$ (s, 1H), 7.47–7.52 (m, 2H), 7.30–7.41 (m, 8H), 4.81 (d, J = 12.0 Hz, 1H), 4.52–4.56 (m, 2H), 3.62 (d, J = 2.4 Hz, 1H), 1.50 ppm (d, J = 6.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.5$, 166.3, 136.9, 131.6 (2CH), 128.4 (2CH), 128.4

Chem. Eur. J. **2014**, 20, 1 – 15

www.chemeurj.org

6



(2 CH), 128.2 (3 CH), 128.1, 123.0, 102.9, 92.3, 80.0, 79.0, 75.8, 71.9 (CH₂), 15.0 ppm; IR (KBr): $\bar{\nu}_{max}$ =2220, 1674, 1581, 1255 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₁H₁₈O₃Na [*M*+Na]⁺: 341.1154; found: 341.2915.

3-Benzyloxy-2-methyl-5-phenylethynyl-2,3-dihydropyran-4one (3 e)

Compound **2e** (0.1 g, 0.29 mmol) was converted to **3e** (0.082 g, 89%) by following general procedure A: eluent, EtOAc/*n*-hexane (5%); $[\alpha]_D^{20} = -186$ (c = 0.1 in MeOH); brown solid; m.p. 96 °C. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.69$ (s, 1 H), 7.48–7.49 (m, 2 H), 7.29–7.40 (m, 8 H), 5.03 (d, J = 11.4 Hz, 1 H), 4.67 (d, J = 12.0 Hz, 1 H), 4.60 (dq, J = 6.6, 9.0 Hz, 1 H), 3.78 (d, J = 9.0 Hz, 1 H), 1.45 ppm (d, J = 7.2 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 189.7$, 165.2, 137.0, 131.6 (2CH), 128.5 (2CH), 128.5 (2CH), 128.2 (3CH), 128.1, 123.0, 103.4, 92.2, 79.5, 79.4, 77.9, 73.7 (CH₂), 17.0 ppm; IR (KBr): $\hat{v}_{max} = 2217$, 1688, 1604, 1588, 1252, 1143 cm⁻¹; HRMS (ESI): m/z calcd for C₂₁H₁₈O₃Na [M+Na]⁺: 341.1154; found: 341.1152.

3-Benzyloxy-2-benzyloxymethyl-5-(4-methoxyphenylethynyl)-2,3-dihydropyran-4-one (3 f)

Compound **2a** (0.1 g, 0.222 mmol) was converted to **3f** (0.089 g, 89%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[\alpha]_D^{20} = +146$ (c=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.72$ (s, 1H), 7.42–7.44 (m, 2H), 7.29–7.37 (m, 10H), 6.83–6.86 (m, 2H), 5.08 (d, J=11.4 Hz, 1H), 4.63 (d, J=10.8 Hz, 1H), 4.59 (d, J=12.0 Hz, 1H), 4.51–4.55 (m, 2H), 4.29 (d, J=11.4 Hz, 1H), 3.82 (m, 2H), 3.82 ppm (s, 3H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 190.5$, 164.9, 159.6, 137.3, 137.2, 133.1 (2CH), 128.5 (4CH), 128.4 (2CH), 128.1, 128.0, 127.8 (2CH), 115.1, 113.9 (2CH), 104.0, 92.3, 81.5, 77.8, 74.5 (CH₂), 73.7, 73.6 (CH₂), 67.7 (CH₂), 55.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2183$, 1607, 1509, 1248 cm⁻¹; HRMS (ESI): m/z calcd for C₂₉H₂₇O₅ [M+H]⁺: 455.1858; found: 455.1334.

3-Benzyloxy-2-benzyloxymethyl-5-(4-methoxyphenylethynyl)-2,3-dihydropyran-4-one (3g)

Compound **2b** (0.1 g, 0.222 mmol) was converted to **3g** (0.063 g, 62%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[a]_D^{20} = +39$ (c=0.1 in MeOH); brown solid; m.p. 84°C. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.76$ (s, 1H), 7.43 (dt, J=2.4, 9.6 Hz, 2H), 7.28–7.37 (m, 10H), 6.84 (dt, J=2.4, 9.6 Hz, 2H), 4.74 (d, J=11.4 Hz, 1H), 4.57 (d, J=11.4 Hz, 1H), 4.53–4.55 (m, 1H), 4.49 (dd, J=6.6, 12.0 Hz, 2H), 3.93 (dd, J=6.6, 9.6 Hz, 1H), 3.81 (s, 3H), 3.80–3.81 (m, 1H), 3.77 ppm (dd, J=6.0, 10.2 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 186.6$, 165.4, 159.6, 137.3, 136.7, 133.1 (2CH), 128.5 (2CH), 128.4 (2CH), 128.4, 128.3, 128.1, 128.0, 127.8 (2CH), 115.0, 113.8 (2CH), 103.8, 92.4, 81.1, 78.3, 73.7 (CH₂), 73.5, 72.0 (CH₂), 67.3 (CH₂), 55.2 ppm; IR (KBr): $\tilde{\nu}_{max} = 2212$, 1699, 1605, 1510, 1259, 1099 cm⁻¹; HRMS (ESI): m/z calcd for C₂₉H₂₆O₅Na [M+Na]⁺: 477.1678; found: 477.2356.

2-(*tert*-Butyldimethylsilanyloxymethyl)-3-hydroxy-5-(4-methoxyphenylethynyl)-2,3-dihydropyran-4-one (3 h)

Compound **2 f** (0.1 g, 0.26 mmol) was converted to **3 h** (0.058 g, 57%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[a]_D^{30} = +171$ (*c*=0.1 in MeOH); white solid; m.p. 104°C. ¹H NMR (300 MHz, CDCl₃): δ =7.82 (s, 1H), 7.43 (d, *J*=8.4 Hz, 2H), 6.86 (d, *J*=8.4 Hz, 2H), 4.46 (d, *J*=12.9 Hz, 1H), 4.22 (d, *J*=13.5 Hz, 1H), 4.13 (dd, *J*=3.6, 12.0 Hz, 1H), 4.05 (dd, *J*=3.6, 12.0 Hz, 1H), 3.83 (s, 3H), 3.56 (brs, 1H), 0.95 (s, 9H), 0.14 ppm (s, 6H); ¹³C NMR

(75 MHz, CDCl₃): δ = 192.3, 167.0, 159.7, 133.1 (2CH), 114.8, 113.9 (2CH), 102.3, 92.2, 83.9, 77.2, 67.0, 61.6 (CH₂), 55.3, 25.8 (3CH₃), 18.4, -5.3, -5.4 ppm; IR (KBr): \tilde{v}_{max} = 2207, 1677, 1607, 1512, 1251, 1240, 1140 cm⁻¹; HRMS (EI): *m/z* calcd for C₂₁H₂₈O₅Si [*M*]⁺: 388.1706; found: 388.1704.

3-Benzyloxy-2-methyl-5-*p*-tolylethynyl-2,3-dihydropyran-4one (3 i)

Compound **2e** (0.1 g, 0.29 mmol) was converted to **3i** (0.085 g, 88%) by following general procedure A: eluent, EtOAc/*n*-hexane (5%); $[\alpha]_{D}^{20} = -164$ (c = 0.1 in MeOH); white solid; m.p. 54°C. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.68$ (s, 1H), 7.29–7.39 (m, 7H), 7.11 (d, J = 7.8 Hz, 2H), 5.03 (d, J = 11.4 Hz, 1H), 4.66 (d, J = 11.7 Hz, 1H), 4.58 (dd, J = 6.6, 9.3 Hz, 1H), 3.77 (d, J = 9.3 Hz, 1H), 2.34 (s, 3H), 1.45 ppm (d, J = 6.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.8$, 165.0, 138.3, 137.0, 131.4 (2CH), 129.0 (2CH), 128.5 (2CH), 128.4 (2CH), 128.1, 119.9, 103.6, 92.4, 79.3, 78.7, 77.9, 73.7 (CH₂), 21.5, 17.0 ppm; IR (KBr): $\ddot{v}_{max} = 2216$, 1689, 1593, 1246, 1148 cm⁻¹; HRMS (ESI): m/z calcd for $C_{22}H_{21}O_3$ [M+H]⁺: 333.1490; found: 333.1439.

3-Benzyloxy-5-(4-methoxyphenylethynyl)-2-methyl-2,3-dihydropyran-4-one (3 j)

Compound **2e** (0.1 g, 0.29 mmol) was converted to **3j** (0.077 g, 76%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[\alpha]_{D}^{20} = -194$ (*c*=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): δ = 7.67 (s, 1H), 7.31–7.44 (m, 7H), 6.83–6.86 (m, 2H), 5.04 (d, *J*=11.4 Hz, 1H), 4.67 (d, *J*=11.4 Hz, 1H), 4.57–4.61 (m, 1H), 3.82 (s, 3H), 3.78 (d, *J*=9.6 Hz, 1H), 1.45 ppm (d, *J*=6.6 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ = 189.9, 164.9, 159.6, 137.1, 133.1 (2 CH), 128.5 (2 CH), 128.5 (2 CH), 128.1, 115.1, 113.9 (2 CH), 103.7, 92.2, 79.3, 78.0, 77.9, 73.7 (CH₂), 55.3, 17.0 ppm; IR (KBr): \hat{v}_{max} = 1694, 1609, 1594, 1509, 1245 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₂H₂₂O₅Na [*M*+Na+H₂O]⁺: 389.1366; found: 389.1379.

3-Benzyloxy-2-benzyloxymethyl-5-(4-nitrophenylethynyl)-2,3-dihydropyran-4-one (3 k)

Compound **2a** (0.1 g, 0.222 mmol) was converted to **3k** (0.06 g, 58%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[\alpha]_D^{20} = +197$ (c=0.1 in MeOH); yellow solid; m.p. 70°C. ¹H NMR (300 MHz, CDCl₃): $\delta = 8.18$ (d, J = 8.7 Hz, 2H), 7.80 (s, 1H), 7.61 (d, J = 8.7 Hz, 2H), 7.31–7.38 (m, 10H), 5.06 (d, J = 11.1 Hz, 1H), 4.62 (d, J = 11.1 Hz, 1H), 4.51–4.59 (m, 3H), 4.31 (d, J = 10.8 Hz, 1H), 3.83 ppm (d, J = 3.0 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.8$, 166.3, 146.9, 137.2, 137.0, 132.1 (2CH), 130.0, 128.5 (4CH), 128.5, 128.2, 128.0, 127.8 (2CH), 123.6 (3CH), 103.0, 90.8, 85.3, 82.0, 74.5 (CH₂), 73.7 (CH₂), 73.6, 67.6 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max}$ 2213, 1681, 1594, 1581, 1522, 1345, 1252 cm⁻¹; HRMS (ESI): m/z calcd for $C_{28}H_{23}NO_6Na$ [M+Na]⁺ 492.1423; found: 492.1452.

3-Benzyloxy-2-benzyloxymethyl-5-(4-nitrophenylethynyl)-2,3-dihydropyran-4-one (3 l)

Compound **2b** (0.1 g, 0.222 mmol) was converted to **3l** (0.052 g, 50%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[\alpha]_D^{20} = +116$ (c=0.2 in MeOH); red gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 8.19$ (d, J = 8.7 Hz, 2H), 7.84 (s, 1H), 7.63 (d, J = 8.7 Hz, 2H), 7.28–7.38 (m, 10H), 4.71–4.77 (m, 1H), 4.48–4.60 (m, 4H), 3.95 (dd, J = 6.9, 10.2 Hz, 1H), 3.85 (d, J = 2.4 Hz, 1H), 3.78 ppm (dd, J = 5.4, 10.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 186.0$, 166.7, 146.9, 137.2, 136.5, 132.1 (2CH), 129.9, 128.5 (2CH), 128.5 (2CH), 128.3 (2CH), 128.2, 128.0, 127.8 (2CH), 123.5 (2CH), 102.8, 90.9, 85.6,

Chem. Eur. J. 2014, 20, 1 – 15 www.

www.chemeurj.org

7

 $\ensuremath{\mathbb{C}}$ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim



81.5, 73.7 (CH₂), 73.3, 72.1 (CH₂), 67.2 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max}$ = 2216, 1582, 1516, 1341 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₈H₂₃NO₆Na [*M*+Na]⁺ 492.1423; found: 492.1390.

2-(*tert*-Butyldimethylsilanyloxymethyl)-3-hydroxy-5-(4-nitrophenylethynyl)-2,3-dihydropyran-4-one (3 m)

Compound **2f** (0.1 g, 0.26 mmol) was converted to **3m** (0.042 g, 40%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[a]_{D}^{2D} = +135$ (c=0.1 in MeOH); yellow solid; m.p. 128 °C. ¹H NMR (300 MHz, CDCl₃): $\delta = 8.21$ (d, J = 8.7 Hz, 2H), 7.91 (s, 1H), 7.63 (d, J = 8.7 Hz, 2H), 4.50 (d, J = 13.2 Hz, 1H), 4.28 (d, J = 13.2 Hz, 1H), 4.15 (dd, J = 3.3, 12.0 Hz, 1H), 4.06 (dd, J = 3.3, 12.0 Hz, 1H), 3.53 (brs, 1H), 0.95 (s, 9H), 0.15 ppm (s, 6H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 191.8$, 168.3, 147.0, 132.2 (2CH), 129.7, 123.6 (2CH), 101.4, 90.7, 84.4, 84.2, 67.0, 61.4 (CH₂), 25.8 (3CH₃), 18.4, -5.4 ppm (2CH₃); IR (KBr): $\tilde{\nu}_{max} = 2213$, 1676, 1583, 1517, 1340, 1250 cm⁻¹; HRMS (ESI): m/z calcd for C₂₀H₂₅NO₆SiNa [M+Na]⁺: 426.1349; found: 426.1346.

3-Benzyloxy-2-benzyloxymethyl-5-(4-bromophenylethynyl)-2,3-dihydropyran-4-one (3 n)

Compound **2b** (0.1 g, 0.222 mmol) was converted to **3n** (0.056 g, 50%) by following general procedure A: eluent, EtOAc/*n*-hexane (10%); $[\alpha]_D^{20} = +88$ (c=0.1 in MeOH); white solid; m.p. 80 °C. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.79$ (s, 1 H), 7.44–7.46 (m, 2 H), 7.29–7.37 (m, 12 H), 4.75 (d, J = 12.0 Hz, 1 H), 4.56–4.59 (m, 2 H), 4.50 (dd, J = 8.4, 11.4 Hz, 2 H), 3.94 (dd, J = 7.2, 10.2 Hz, 1 H), 3.82 (d, J = 3.0 Hz, 1 H), 3.78 ppm (dd, J = 5.4, 10.2 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 186.3$, 165.9, 137.3, 136.6, 133.0 (2 CH), 131.5 (2 CH), 128.5 (2 CH), 128.5 (2 CH), 128.4 (2 CH), 128.2, 128.0, 127.8 (2 CH), 122.5, 121.9, 103.3, 91.5, 81.3, 81.0, 73.7 (CH₂), 73.4, 72.1 (CH₂), 67.3 ppm (CH₂); IR (KBr): $\bar{\nu}_{max} = 2220$, 1684, 1595, 1580, 1485, 1368, 1261, 1171, 1101, 1070 cm⁻¹; HRMS (ESI): m/z calcd for C₂₈H₂₃BrO₄Na [*M*+Na]⁺: 525.0678; found: 525.1106.

3-Benzyloxy-5-trimethylsilanylethynyl-2,3-dihydropyran-4-one (3 o)

Compound **2g** (0.1 g, 0.30 mmol) was converted to **3o** (0.068 g, 75%) by following general procedure A: eluent, EtOAc/*n*-hexane (15%); $[a]_{D}^{20} = -24$ (c = 0.1 in MeOH); yellowish white solid; m.p. 70 °C. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.72$ (s, 1 H), 7.31–7.37 (m, 5 H), 4.85 (d, J = 11.7 Hz, 1 H), 4.60 (d, J = 11.7 Hz, 1 H), 4.55 (dd, J = 5.7, 12.6 Hz, 1 H), 4.40 (dd, J = 3.6, 12.6 Hz, 1 H), 3.83–3.86 (m, 1 H), 0.23 ppm (s, 9 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.1$, 167.0, 136.8, 128.5 (2CH), 128.2 (2CH), 128.1, 103.8, 97.7, 95.0, 72.7, 72.4 (CH₂), 71.9 (CH₂), -0.08 ppm (3 CH₃); IR (KBr): $\tilde{\nu}_{max} = 2158$, 1676, 1587, 1192 cm⁻¹; HRMS (ESI): *m/z* calcd for C₁₇H₂₀O₃SiNa [*M*+Na]⁺: 323.1080; found: 322.6480.

3-Benzyloxy-2-benzyloxymethyl-5-trimethylsilanylethynyl-2,3-dihydropyran-4-one (3 p)

Compound **2b** (0.1 g, 0.222 mmol) was converted to **3p** (0.067 g, 72%) by following general procedure A: eluent, EtOAc/*n*-hexane (8%); $[\alpha]_{D}^{20} = +70$ (c=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.73$ (s, 1H), 7.26–7.37 (m, 10H), 4.73 (d, J = 12.0 Hz, 1H), 4.56 (d, J = 11.4 Hz, 1H), 4.46–4.50 (m, 3H), 3.90 (dd, J = 6.6, 9.6 Hz, 1H), 3.77 (d, J = 2.4 Hz, 1H), 3.75 (dd, J = 5.4, 10.2 Hz, 1H), 0.23 ppm (s, 9H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 186.4$, 166.7, 137.3, 136.7, 128.5 (2CH), 128.4 (2CH), 128.3 (2CH), 128.1, 128.0, 127.8 (2CH), 103.6, 97.9, 95.2, 81.2, 73.7 (CH₂), 73.3, 72.0 (CH₂), 67.3

(CH₂), -0.04 ppm (3CH₃); IR (KBr): $\tilde{\nu}_{max}$ =2158, 1687, 1589, 1250, 1203, 1104 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₅H₂₉O₄Si [*M*+H]⁺: 421.1835; found: 421.2083.

3-Benzyloxy-2-benzyloxymethyl-5-hex-1-ynyl-2,3-dihydropyran-4-one (3 q)

Compound **2b** (0.1 g, 0.222 mmol) was converted to **3q** (0.0467 g, 52%) by following general procedure B: eluent, EtOAc/*n*-hexane (6%); $[\alpha]_D^{20} = +50$ (c = 0.1 in MeOH); yellow solid; m.p. 55°C. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.63$ (s, 1 H), 7.29–7.37 (m, 10 H), 4.71 (d, J = 12.0 Hz, 1 H), 4.56 (d, J = 11.7 Hz, 1 H), 4.44–4.50 (m, 3 H), 3.90 (dd, J = 6.9, 9.9 Hz, 1 H), 3.72–3.77 (m, 2 H), 2.38 (t, J = 6.9 Hz, 2 H), 1.51–1.58 (m, 2 H), 1.39–1.47 (m, 2 H), 0.92 ppm (t, J = 7.5 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.1$, 165.2, 137.4, 136.8, 128.5 (2 CH), 128.4 (2 CH), 128.4 (2 CH), 128.1, 128.0, 127.8 (2 CH), 103.9, 93.6, 81.0, 73.7 (CH₂), 73.5, 72.0 (CH₂), 70.4, 67.4 (CH₂), 30.8 (CH₂), 22.0 (CH₂), 19.2 (CH₂), 13.6 ppm (CH₃); IR (KBr): $\vec{v}_{max} = 2363$, 1673, 1583, 1221 cm⁻¹; HRMS (ESI): m/z calcd for C₂₆H₂₈O₄ [M+Na]⁺: 427.1886; found: 427.2039; HRMS (ESI): m/z calcd for C₂₆H₂₈O₄ [M+Na]⁺H₂O]⁺: 445.1992; found: 445.1985.

3-Benzyloxy-2-benzyloxymethyl-5-hex-1-ynyl-2,3-dihydropyran-4-one (3 r)

Compound **2a** (0.1 g, 0.222 mmol) was converted to **3r** (0.05 g, 56%) by following general procedure B: eluent, EtOAc/*n*-hexane (6%); $[\alpha]_D^{20} = +114$ (c=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.58$ (s, 1H), 7.28–7.34 (m, 10H), 5.06 (d, J= 10.8 Hz, 1H), 4.59 (d, J=10.8 Hz, 1H), 4.49–4.57 (m, 2H), 4.45 (dt, J=3.0, 11.4 Hz, 1H), 4.23 (d, J=10.8 Hz, 1H), 3.78 (d, J=3.0 Hz, 2H), 2.37 (t, J=7.2 Hz, 2H), 1.52–1.57 (m, 2H), 1.40–1.47 (m, 2H), 0.92 ppm (t, J=7.2 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 192.0$, 165.7, 138.4, 138.2, 129.5 (4CH), 129.4 (2CH), 129.1, 128.9, 128.8 (2CH), 105.1, 94.5, 82.3, 75.4 (CH₂), 74.6 (CH₂), 74.6, 70.9, 68.7 (CH₂), 31.8 (CH₂), 23.0 (CH₂), 20.2 (CH₂), 14.6 ppm (CH₃); IR (neat): $\hat{v}_{max} = 2363$, 1695, 1598, 1207 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₆H₂₈O₄ [*M*+Na+H₂O]⁺: 445.1992; found: 445.1560.

3-Benzyloxy-2-benzyloxymethyl-5-cyclopentylethynyl-2,3-dihydropyran-4-one (3 s)

Compound **2a** (0.1 g, 0.222 mmol) was converted to **3s** (0.048 g, 52%) by following general procedure B: eluent, EtOAc/*n*-hexane (7.5%); $[a]_{20}^{20} = +25$ (c=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.58$ (s, 1H), 7.27–7.36 (m, 10H), 5.06 (d, J= 11.4 Hz, 1H), 4.59 (d, J= 10.8 Hz, 1H), 4.50–4.57 (m, 2H), 4.44 (dt, J= 3.0, 11.4 Hz, 1H), 4.23 (d, J= 11.4 Hz, 1H), 3.78 (d, J= 3.0 Hz, 2H), 2.78 (quin, J= 7.2 Hz, 1H), 1.94–1.99 (m, 2H), 1.71–1.77 (m, 2H), 1.63–1.68 (m, 2H), 1.53–1.60 ppm (m, 2H); ¹³C NMR (150 MHz, CDCl₃): $\delta =$ 192.0, 165.6, 138.4, 138.2, 129.5 (4CH), 129.4 (2CH), 129.1, 128.9, 128.8 (2CH), 105.1, 98.6, 82.3, 75.4 (CH₂), 74.7, 74.6 (CH₂), 70.4, 68.7 (CH₂), 34.8 (2CH₂), 31.8, 26.0 ppm (2CH₂); IR (neat): $\tilde{\nu}_{max} =$ 2363, 1694, 1598, 1210 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₇H₂₈O₄ [*M*+Na+H₂O]⁺: 457.1992; found: 457.1516.

General procedure for the synthesis of 4a-s

In a 25 mL flame-dried, two-necked, round-bottomed flask equipped with a magnetic stir bar the corresponding substituted ethynyl-2,3-dihydro-pyran-4-one (**3 a**-**s**) was dissolved in dry THF (2.5 mL) at room temperature under an argon atmosphere. AuCl₃ [mol%] or PPh₃AuNTf₂ [mol%] or PPh₃AuCl+AgOTf [mol%] was added to the reaction mixtures and stirred for the required times.

Chem. Eur. J. 2014, 20, 1–15

www.chemeurj.org

8



The resulting reaction mixtures were quenched with H₂O, saturated NH₄Cl solution was added, and the product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was purified by using silica gel column chromatography (230-400; EtOAc/nhexane) to afford 4a-s.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-phenylfuran-3-carbaldehyde (4 a)

Compound 3a (0.05 g, 0.117 mmol) was converted to 4a (0.05 g, 96%) by following the general procedure: eluent, EtOAc/n-hexane (25%); $[\alpha]_{D}^{20} = +59$ (c=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.01$ (s, 1 H), 7.68–7.69 (m, 2 H), 7.40–7.43 (m, 2H), 7.29-7.36 (m, 9H), 7.23-7.24 (m, 2H), 6.99 (s, 1H), 4.93 (d, J=7.8 Hz, 1 H), 4.61 (d, J=11.4 Hz, 1 H), 4.56 (d, J=12.0 Hz, 1 H), 4.52 (d, J = 11.4 Hz, 1 H), 4.43 (d, J = 12.0 Hz, 1 H), 4.31 (dt, J = 4.2, 7.2 Hz, 1 H), 3.74 (dd, J=4.8, 9.6 Hz, 1 H), 3.70 (dd, J=3.6, 9.0 Hz, 1 H), 2.57 ppm (brs, 1 H); 13 C NMR (150 MHz, CDCl₃): $\delta = 185.2$ (d, 1C), 159.5, 154.9, 137.6, 136.8, 129.3, 128.8 (2CH), 128.5 (2CH), 128.5, 128.5 (2CH), 128.3, 128.2, 128.1 (2CH), 127.9, 127.8 (2CH), 124.3 (2 CH), 102.6, 73.8, 73.6 (CH_2), 71.8 (CH_2), 71.7, 70.2 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max} = 1678 \text{ cm}^{-1}$; HRMS (EI): m/z calcd for C₂₈H₂₆O₅ [*M*]⁺: 442.1780; found: 442.1777.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-phenylfuran-3-carbaldehyde (4b)

Compound **3b** (0.05 g, 0.117 mmol) was converted to **4b** (0.033 g, 63%) by following the general procedure: eluent, EtOAc/n-hexane (25%); $[\alpha]_{D}^{20} = -2$ (c = 0.1 in MeOH); yellow gum. ¹H NMR (300 MHz, $CDCI_3$): $\delta = 10.0$ (s, 1 H), 7.65–7.68 (m, 2 H), 7.19–7.45 (m, 13 H), 6.95 (s, 1 H), 5.03 (d, J=6.9 Hz, 1 H), 4.66 (d, J=11.4 Hz, 1 H), 4.51 (d, J= 11.7 Hz, 1 H), 4.44-4.45 (m, 2 H), 4.24-4.27 (m, 1 H), 3.60 (dd, J=3.9, 10.2 Hz, 1 H), 3.36 (dd, J=4.8, 10.2 Hz, 1 H), 2.89 ppm (d, J=3.6 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃): δ=185.0, 158.7, 155.0, 137.4, 136.7, 129.1, 128.8 (2CH), 128.6 (2CH), 128.6 (2CH), 128.3 (2CH), 128.2 (2CH), 128.1 (2CH), 127.9, 127.8, 124.2 (2CH), 102.5, 74.7, 73.6 (CH₂), 72.5, 72.1 (CH₂), 69.9 ppm (CH₂); IR (neat): $\tilde{\nu}_{max} = 1678 \text{ cm}^{-1}$; HRMS (ESI): *m/z* calcd for C₂₈H₂₆O₅Na [*M*+Na]⁺: 465.1678; found: 465.1669.

2-[3-(tert-Butyldimethylsilanyloxy)-1,2-dihydroxypropyl]-5phenylfuran-3-carbaldehyde (4 c)

Compound 3c (0.05 g, 0.14 mmol) was converted to 4c (0.026 g, 49%) by following the general procedure: eluent, EtOAc/n-hexane (25%); $[\alpha]_{D}^{20} = -1$ (*c*=0.1 in MeOH); brown gum. ¹H NMR (300 MHz, $CDCl_3$): $\delta = 10.14$ (s, 1 H), 7.65–7.68 (m, 2 H), 7.29–7.44 (m, 3 H), 6.99 (s, 1 H), 5.16-5.19 (m, 1 H), 4.03-4.05 (m, 2 H), 3.82 (dd, J=4.2, 10.5 Hz, 1 H), 3.73 (dd, J=4.5, 10.5 Hz, 1 H), 2.82 (d, J=5.4 Hz, 1 H), 0.91 (s, 9 H), 0.09 ppm (s, 6 H); ^{13}C NMR (75 MHz, CDCl_3): $\delta\!=\!186.7,$ 160.7, 154.2, 129.2, 128.8 (2CH), 128.5, 126.4, 124.2 (2CH), 103.5, 73.2, 69.5, 64.0 (CH₂), 25.8 (3CH₃), 18.2, -5.5 ppm (2CH₃); IR (KBr): $\tilde{\nu}_{max} = 1673$, 1121 cm⁻¹; HRMS (ESI): m/z calcd for C₂₀H₂₈O₅SiNa [*M*+Na]⁺: 399.1604; found: 399.1870.

2-(1-Benzyloxy-2-hydroxypropyl)-5-phenylfuran-3-carbaldehyde (4d)

Compound 3d (0.05 g, 0.157 mmol) was converted to 4d (0.023 g, 43%) by following the general procedure: eluent, EtOAc/n-hexane (25%); $[\alpha]_{D}^{20} = +27$ (c=0.1 in MeOH); yellow gum. ¹H NMR

Chem. Eur. J. 2014, 20, 1-15

www.chemeurj.org

9

(300 MHz, CDCl_3): $\delta = 10.05$ (s, 1 H), 7.68–7.71 (m, 2 H), 7.30–7.46 (m, 8H), 6.98 (s, 1H), 4.66 (d, J=11.4 Hz, 1H), 4.62 (d, J=7.8 Hz, 1 H), 4.51 (d, J=11.4 Hz, 1 H), 4.21-4.25 (m, 1 H), 2.89 (m, 1 H), 1.11 ppm (d, J = 6.3 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 184.8$, 159.0, 155.1, 136.6, 129.1, 128.9 (2CH), 128.7, 128.7 (2CH), 128.3, 128.1 (2CH), 127.9, 124.3 (2CH), 102.7, 79.3, 72.1 (CH₂), 69.8, 18.0 ppm; IR (KBr): $\tilde{\nu}_{max} = 1679 \text{ cm}^{-1}$; HRMS (ESI): m/z calcd for C₂₁H₂₀O₄Na [*M*+Na]⁺: 359.1260; found: 359.1257.

2-(1-Benzyloxy-2-hydroxypropyl)-5-phenylfuran-3-carbaldehyde (4e)

Compound 3e (0.05 g, 0.157 mmol) was converted to compound 4e (0.034 g, 64%) by following the general procedure: eluent, EtOAc/*n*-hexane (20%); $[a]_{D}^{20} = -3$ (*c*=0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.06$ (s, 1 H), 7.69 (d, J = 7.2 Hz, 2 H), 7.43 (t, J=7.8 Hz, 2 H), 7.29–7.36 (m, 6 H), 7.01 (s, 1 H), 4.75 (d, J= 4.8 Hz, 1 H), 4.69 (d, J=12.0 Hz, 1 H), 4.49 (d, J=11.4 Hz, 1 H), 4.27-4.31 (m, 1 H), 2.20 (brs, 1 H), 1.24 ppm (d, J=6.0 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): δ = 185.7, 159.0, 154.9, 136.8, 129.3, 128.9 (2 CH), 128.6 (2CH), 128.6, 128.3, 128.2, 128.1 (2CH), 124.2 (2CH), 102.8, 78.4, 72.0 (CH₂), 69.3, 18.7 ppm (CH₃); IR (KBr): $\tilde{\nu}_{max} = 1678 \text{ cm}^{-1}$; HRMS (ESI): m/z calcd for $C_{21}H_{20}O_4Na$ [*M*+Na]⁺: 359.1260; found: 359.1257.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-(4-methoxyphenyl)furan-3-carbaldehyde (4 f)

Compound 3f (0.05 g, 0.11 mmol) was converted to 4f (0.044 g, 84%) by following the general procedure: eluent, EtOAc/n-hexane (30%); $[\alpha]_{D}^{20} = +75$ (c=0.1 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): δ = 9.99 (s, 1 H), 7.61–7.62 (m, 2 H), 7.28–7.36 (m, 8H), 7.23–7.24 (m, 2H), 6.93–6.95 (m, 2H), 6.85 (s, 1H), 4.92 (d, J= 7.2 Hz, 1 H), 4.61 (d, J=11.4 Hz, 1 H), 4.56 (d, J=12.0 Hz, 1 H), 4.52 (d, J=11.4 Hz, 1 H), 4.42 (d, J=11.4 Hz, 1 H), 4.31 (m, 1 H), 3.85 (s, 3 H), 3.74 (dd, J=4.8, 9.6 Hz, 1 H), 3.70 (dd, J=4.2, 9.6 Hz, 1 H), 2.55 ppm (brs, 1H); 13 C NMR (150 MHz, CDCl₃): δ = 185.2 (d, 1C), 159.9, 158.9, 155.1, 137.6, 136.9, 128.5 (2CH), 128.5 (2CH), 128.5, 128.2, 128.1 (2CH), 127.9, 127.9 (2CH), 125.8 (2CH), 122.3, 114.2 (2 CH), 100.9, 73.8, 73.6 (CH₂), 71.7, 71.7 (CH₂), 70.2 (CH₂), 55.4 ppm; IR (KBr): $\tilde{\nu}_{max} = 1677$, 1502 cm⁻¹; HRMS (EI): m/z calcd for C₂₉H₂₈O₆ [*M*]⁺: 472.1886; found: 472.1895.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-(4-methoxyphenyl)furan-3-carbaldehyde (4g)

Compound 3g (0.05 g, 0.11 mmol) was converted to 4g (0.040 g, 77%) by following the general procedure: eluent, EtOAc/n-hexane (25%); $[\alpha]_{D}^{20} = -89$ (c = 0.1 in MeOH); yellow gum. ¹H NMR (300 MHz, CDCl₃): δ = 9.98 (s, 1 H), 7.59 (d, J = 8.7 Hz, 2 H), 7.20–7.31 (m, 10 H), 6.95 (d, J=8.7 Hz, 2 H), 6.81 (s, 1 H), 5.01 (d, J=6.9 Hz, 1 H), 4.66 (d, J=11.4 Hz, 1 H), 4.51 (d, J=11.4 Hz, 1 H), 4.40-4.45 (m, 2H), 4.24-4.28 (m, 1H), 3.86 (s, 3H), 3.59 (dd, J=3.6, 9.9 Hz, 1H), 3.36 (dd, J=4.5, 10.2 Hz, 1 H), 2.87 ppm (brs, 1 H); ¹³C NMR (75 MHz, CDCl₃): δ = 185.0, 160.0, 158.1, 155.2, 137.4, 136.7, 128.6 (2CH), 128.4 (2CH), 128.3 (2CH), 128.2 (2CH), 128.1, 127.8 (2CH), 125.8 (2CH), 122.1, 114.3 (2CH), 100.8, 74.6, 73.6 (CH₂), 72.6, 72.1 (CH₂), 69.9 (CH₂), 55.4 ppm; IR (KBr): $\tilde{\nu}_{max} = 1676$, 1501, 1252 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₉H₂₈O₆Na [*M*+Na]⁺: 495.1784; found: 495.1786.



2-[3-(*tert*-Butyldimethylsilanyloxy)-1,2-dihydroxypropyl]-5-(4-methoxyphenyl)-furan-3-carbaldehyde (4 h)

Compound **3h** (0.05 g, 0.128 mmol) was converted to **4h** (0.018 g, 33%) by following the general procedure: eluent, EtOAc/*n*-hexane (30%); $[\alpha]_D^{20} = -0.1$ (c = 0.05 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.04$ (s, 1 H), 7.58 (d, J = 8.4 Hz, 2 H), 6.93 (d, J = 9.0 Hz, 2 H), 6.84 (s, 1 H), 5.06 (m, 1 H), 4.17 (d, J = 6.6 Hz, 1 H), 4.00 (brs, 1 H), 3.89 (dd, J = 4.2, 10.2 Hz, 1 H), 3.84 (s, 3 H), 3.82 (dd, J = 4.2, 10.2 Hz, 1 H), 0.90 (s, 9 H), 0.09 ppm (s, 6 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 187.0$ (d, 1 C), 160.9, 159.9, 154.3, 125.7 (2 CH), 125.7, 122.1, 114.2 (2 CH), 102.2, 72.7, 69.8, 63.8 (CH₂), 55.3, 25.8 (3 CH₃), 18.2, -5.5 ppm (2 CH₃); IR (KBr): $\hat{v}_{max} = 1671$ cm⁻¹; HRMS (ESI): m/z calcd for C₂₁H₃₀O₆SiNa [M+Na]⁺: 429.1710; found: 429.0250.

2-(1-Benzyloxy-2-hydroxypropyl)-5-*p*-tolylfuran-3-carbaldehyde (4i)

Compound **3i** (0.05 g, 0.15 mmol) was converted to **4i** (0.037 g, 72%) by following the general procedure: eluent, EtOAc/*n*-hexane (25%); $[\alpha]_D^{20} = -124$ (c = 0.1 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.05$ (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.21–7.38 (m, 7H), 6.94 (s, 1H), 4.74 (d, J = 5.1 Hz, 1H), 4.68 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.25–4.30 (m, 1H), 2.38 (s, 3H), 2.19 (d, J = 4.8 Hz, 1H), 1.24 ppm (d, J = 6.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 185.8$, 158.9, 155.1, 138.6, 136.9, 129.5 (2CH), 128.6 (2CH), 128.2 (2CH), 128.1 (2CH), 126.6, 124.2 (2CH), 102.0, 78.4, 71.9 (CH₂), 69.2, 21.3, 18.8 ppm (CH₃); IR (KBr): $\bar{v}_{max} = 1676$ cm⁻¹; HRMS (ESI): m/z calcd for $C_{22}H_{22}O_4$ Na $[M+Na]^+$: 373.1416; found: 373.1413.

2-(1-Benzyloxy-2-hydroxypropyl)-5-(4-methoxyphenyl)furan-3-carbaldehyde (4j)

Compound **3j** (0.05 g, 0.143 mmol) was converted to **4j** (0.035 g, 67%) by following the general procedure: eluent, EtOAc/*n*-hexane (30%); $[\alpha]_{\rm D}^{20} = -120$ (c = 0.1 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.04$ (s, 1H), 7.61 (d, J = 8.7 Hz, 2H), 7.31–7.37 (m, 5H), 6.95 (d, J = 8.7 Hz, 2H), 6.87 (s, 1H), 4.73 (d, J = 4.8 Hz, 1H), 4.68 (d, J = 11.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.27–4.29 (m, 1H), 3.85 (s, 3H), 2.17 (d, J = 4.8 Hz, 1H), 1.24 ppm (d, J = 6.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 185.7$, 159.9, 158.5, 155.0, 136.9, 128.6 (2 CH), 128.3, 128.2, 128.1 (2 CH), 125.8 (2 CH), 122.2, 114.3 (2 CH), 101.1, 78.3, 71.9 (CH₂), 69.3, 55.4, 18.8 ppm (CH₃); IR (KBr): $\tilde{\nu}_{\rm max} = 1676$, 1502, 1252 cm⁻¹; HRMS (EI): m/z calcd for C₂₂H₂₂O₅ [M]⁺: 366.1467; found: 366.1466.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-(4-nitrophenyl)furan-3-carbaldehyde (4k)

Compound **3k** (0.05 g, 0.106 mmol) was converted to **4k** (0.022 g, 42%) by following the general procedure: eluent, EtOAc/*n*-hexane (30%); $[\alpha]_D^{20} = -40$ (c = 0.05 in MeOH); reddish gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.02$ (s, 1H), 8.28 (d, J = 9.0 Hz, 2H), 7.81 (d, J = 9.0 Hz, 2H), 7.29–7.37 (m, 8H), 7.22 (d, J = 6.6 Hz, 2H), 7.19 (s, 1H), 4.95 (d, J = 7.2 Hz, 1H), 4.60 (d, J = 11.4 Hz, 1H), 4.57 (d, J = 11.4, 1H), 4.53 (d, J = 11.4 Hz, 1H), 4.46 (d, J = 11.4 Hz, 1H), 4.27–4.30 (m, 1H), 3.76 (dd, J = 4.8, 9.6 Hz, 1H), 3.70 (dd, J = 4.2, 9.6 Hz, 1H), 2.56 ppm (brs, 1H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 184.8$ (d, 1C), 161.3, 152.4, 147.2, 137.4, 136.6, 135.0, 128.6 (2CH), 128.5 (2CH), 128.4, 128.3, 128.1 (2CH), 128.0, 127.9 (2CH), 124.6 (2CH), 124.4 (2CH), 106.5, 73.9, 73.6 (CH₂), 72.1 (CH₂), 71.7, 70.0 ppm

(CH₂); IR (KBr): $\tilde{\nu}_{max}$ 1680, 1602, 1516, 1343 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₈H₂₅NO₇Na [*M*+Na]⁺: 510.1529; found: 510.1526.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-(4-nitrophenyl)furan-3-carbaldehyde (41)

Compound **3I** (0.05 g, 0.106 mmol) was converted to **4I** (0.027 g, 53%) following the general procedure: eluent, EtOAc/*n*-hexane (25%); $[\alpha]_D^{20} = -1$ (c = 0.1 in MeOH); yellow gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.02$ (s, 1H), 8.28 (d, J = 8.7 Hz, 2H), 7.77 (d, J = 9.0 Hz, 2H), 7.19–7.36 (m, 10H), 7.14 (s, 1H), 5.04 (d, J = 6.3 Hz, 1H), 4.67 (d, J = 11.4 Hz, 1H), 4.55 (d, J = 11.4 Hz, 1H), 4.45 (m, 2H), 4.22–4.24 (m, 1H), 3.62 (dd, J = 4.5, 10.2 Hz, 1H), 3.42 ppm (dd, J = 4.5, 10.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 184.7$, 160.5, 152.4, 147.3, 137.3, 136.5, 134.8, 128.7 (2CH), 128.4 (2CH), 128.2 (2CH), 128.0, 127.9 (2CH), 127.8 (2CH), 124.6 (2CH), 124.4 (2CH), 106.4, 74.9, 73.7 (CH₂), 72.6 (CH₂), 72.4, 69.9 ppm (CH₂); IR (KBr): $\bar{\nu}_{max} = 1598$, 1516, 1339 cm⁻¹; HRMS (ESI): m/z calcd for C₂₈H₂₅NO₇Na [M+Na]⁺: 510.1529; found: 510.1527.

2-[3-(*tert*-Butyldimethylsilanyloxy)-1,2-dihydroxypropyl]-5-(4-nitrophenyl)furan-3-carbaldehyde (4m)

Compound **3m** (0.05 g, 0.124 mmol) was converted to **4m** (0.011 g, 21%) by following the general procedure: eluent, EtOAc/ *n*-hexane (25%); $[a]_{20}^{20} = -60$ (c = 0.1 in MeOH); reddish solid; m.p. 72°C. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.09$ (s, 1H), 8.29 (d, J = 9.0 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.23 (s, 1H), 5.09 (d, J = 6.6 Hz, 1H), 4.14 (brs, 1H), 4.01–4.03 (m, 1H), 3.91 (dd, J = 3.6, 10.2 Hz, 1H), 3.84 (dd, J = 4.2, 10.8 Hz, 1H), 2.74 (brs, 1H), 0.92 (s, 9H), 0.11 ppm (d, J = 1.2 Hz, 6H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 186.5$ (d, 1C), 163.3, 151.7, 147.2, 134.9, 125.9, 124.5 (2CH), 124.4 (2CH), 107.8, 72.6, 69.8, 63.6 (CH₂), 25.8 (3CH₃), 18.2, -5.5 ppm (2CH₃); IR (KBr): $\hat{v}_{max} = 1685$, 1673, 1524, 1345 cm⁻¹; HRMS (ESI): m/z calcd for C₂₀H₂₇NO₇SiNa [*M*+Na]⁺: 444.1455; found: 444.1710.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-(4-bromophenyl)furan-3-carbaldehyde (4 n)

Compound **3n** (0.05 g, 0.099 mmol) was converted to **4n** (0.034 g, 67%) by following the general procedure: eluent, EtOAc/*n*-hexane (25%); $[\alpha]_D^{20} = -30$ (c = 0.1 in MeOH); white solid; m.p. 95 °C. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.0$ (s, 1 H), 7.50–7.56 (m, 4H), 7.20–7.34 (m, 10 H), 6.94 (s, 1 H), 5.02 (d, J = 7.2 Hz, 1 H), 4.65 (d, J = 11.4 Hz, 1 H), 4.52 (d, J = 11.4 Hz, 1 H), 4.46 (d, J = 12.0, Hz, 1 H), 4.43 (d, J = 11.4 Hz, 1 H), 4.23 (dt, J = 4.2, 6.6 Hz, 1 H), 3.60 (dd, J = 4.2, 10.2 Hz, 1 H), 3.38 (dd, J = 4.2, 10.2 Hz, 1 H), 2.83 ppm (brs, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 184.9$ (d, 1 C), 159.0, 153.9, 137.4, 136.6, 132.1 (2 CH), 128.6 (2 CH), 128.4 (2 CH), 128.3, 128.2 (2 CH), 128.1, 127.9, 127.8, 127.8 (2 CH), 125.7 (2 CH), 122.6, 103.1, 74.7, 73.6 (CH₂), 72.5, 72.3 (CH₂), 69.8 ppm (CH₂); IR (KBr): $\tilde{v}_{max} = 1642$, 1546, 1496, 1478, 1452 cm⁻¹; HRMS (ESI): m/z calcd for C₂₈H₂₅O₅BrNa [M+Na]⁺: 543.0783; found: 543.0782.

2-(1-Benzyloxy-2-hydroxyethyl)-5-trimethylsilanylfuran-3carbaldehyde (4 o), 2-(1-benzyloxy-2-hydroxyethyl)-4-trimethylsilanylfuran-3-carbaldehyde (4 oa), and 2-(1-benzyloxy-2hydroxyethyl)furan-3-carbaldehyde (4 ob)

Compound **30** (0.05 g, 0.166 mmol) was converted to **40** (0.005 g, 9%), **40a** (0.006 g, 11%), and **40b** (0.0065 g, 16%) by following the general procedure. Compound **40**: eluent, EtOAc/*n*-hexane (20%); $[\alpha]_D^{20} = -1$ (*c*=0.11 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.06$ (s, 1H), 7.27–7.35 (m, 5H), 6.95 (s, 1H),

Chem. Eur. J. **2014**, 20, 1–15

www.chemeurj.org

 $\ensuremath{^{\odot}}$ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

N These are not the final page numbers!

10



4.97 (dd, J = 4.2, 7.8 Hz, 1 H), 4.62 (d, J = 12.0 Hz, 1 H), 4.49 (d, J =11.4 Hz, 1 H), 3.99 (dd, J=7.8, 12.0 Hz, 1 H), 3.86 (dd, J=4.2, 12.0 Hz, 1 H), 2.24 (br s, 1 H), 0.29 ppm (s, 9 H); $^{13}\mathrm{C}$ NMR (150 MHz, CDCl₃): $\delta = 185.4$ (d, 1C), 163.4, 162.5, 136.9, 128.6 (2CH), 128.2, 128.1 (2CH), 125.9, 117.9, 75.5, 72.0 (CH₂), 64.7 (CH₂), -1.9 ppm (3 CH₃); IR (KBr): $\tilde{\nu}_{max} = 1678$, 1251 cm⁻¹; HRMS (ESI): m/z calcd for C₁₇H₂₂O₄SiNa [*M*+Na]⁺: 341.1185; found: 341.1183. Compound **4 oa**: eluent, EtOAc/*n*-hexane (20%); $[\alpha]_{D}^{20} = +24$ (*c*=0.1 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.07$ (s, 1 H), 7.25– 7.35 (m, 6H), 4.96 (dd, J=3.6, 7.2 Hz, 1H), 4.62 (d, J=12.0 Hz, 1H), 4.48 (d, J=11.4 Hz, 1 H), 3.99 (dd, J=7.8, 12.0 Hz, 1 H), 3.84 (dd, J= 4.2, 12.0 Hz, 1 H), 2.20 (br s, 1 H), 0.26 ppm (s, 9 H); $^{13}\mathrm{C}\ \mathrm{NMR}$ (150 MHz, CDCl₃): δ = 185.4 (d, 1C), 161.4, 148.6, 136.8, 129.1, 128.6 (2CH), 128.2, 128.0 (2CH), 119.0, 74.7, 71.9 (CH₂), 64.6 (CH₂), $-1.1 \text{ ppm } (3 \text{ CH}_3); \text{ IR (KBr): } \tilde{\nu}_{max} = 1679 \text{ cm}^{-1}; \text{ HRMS (ESI): } m/z \text{ calcd}$ for C₁₇H₂₂O₄SiNa [*M*+Na]⁺: 341.1185; found: 341.1182. Compound **4 ob**: eluent, EtOAc/*n*-hexane (30%); $[\alpha]_{D}^{20} = +35.2$ (*c*=0.5 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.05$ (s, 1 H), 7.43 (d, J=1.8 Hz, 1 H), 7.28-7.36 (m, 5 H), 6.78 (d, J=1.8 Hz, 1 H), 4.96 (dd, J=4.2, 7.2 Hz, 1 H), 4.63 (d, J=11.4 Hz, 1 H), 4.48 (d, J= 11.4 Hz, 1 H), 3.99 (dd, J=7.2, 11.4 Hz, 1 H), 3.86 (dd, J=4.2, 12.0 Hz, 1 H), 2.20 ppm (brs, 1 H); 13 C NMR (150 MHz, CDCl₃): $\delta =$ 185.1 (d, 1C), 159.5, 143.6, 136.7, 128.7 (2CH), 128.3, 128.1 (2CH), 125.8, 108.5, 74.8, 71.9 (CH₂), 64.5 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max} =$ 1679 cm⁻¹; HRMS (ESI): m/z calcd for $C_{14}H_{14}O_4Na$ [M+Na]⁺: 269.0790; found: 269.0792.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-trimethylsilanylfuran-3-carbaldehyde (4 p) and 2-(1,3-bis(benzyloxy)-2-hydroxypropyl)furan-3-carbaldehyde (4 pb)

Compound **3p** (0.05 g, 0.118 mmol) was converted to **4p** (0.018 g, 35%) and 4pb (0.013 g, 30%) by following the general procedure with AuCl₃ as catalyst. Compound **4p**: eluent, EtOAc/n-hexane (20%); $[\alpha]_{D}^{20} = -1$ (c=0.1 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): δ = 10.0 (s, 1 H), 7.24–7.30 (m, 10 H), 6.92 (s, 1 H), 4.97 (d, J=6.6 Hz, 1 H), 4.58 (d, J=11.4 Hz, 1 H), 4.43-4.48 (m, 3 H), 4.18-4.19 (m, 1 H), 3.54 (dd, J=4.2, 10.2 Hz, 1 H), 3.27 (dd, J=4.8, 10.2 Hz, 1 H), 2.82 (d, J=3.6 Hz, 1 H), 0.26 ppm (s, 9 H); ¹³C NMR (75 MHz, CDCl₃): δ = 185.3, 163.4, 162.5, 137.5, 136.8, 128.6 (2 CH), 128.4 (2CH), 128.2 (2CH), 128.1 (2CH), 127.8 (2CH), 126.3, 117.7, 75.1, 73.6 (CH₂), 72.6, 72.2 (CH₂), 69.9 (CH₂), -1.9 ppm (3CH₃); IR (neat): $\tilde{\nu}_{max} =$ 1680 cm⁻¹; HRMS (ESI): m/z calcd for C₂₅H₃₀O₅SiNa [*M*+Na]⁺: 461.1761; found: 461.1762. Compound **4pb**: eluent, EtOAc/*n*-hexane (30%); $[\alpha]_D^{20} = -116$ (*c* = 0.1 in MeOH); yellow gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 9.98$ (s, 1 H), 7.40 (d, J = 1.8 Hz, 1 H), 7.22–7.34 (m, 10 H), 6.75 (d, J=2.4 Hz, 1 H), 4.99 (d, J=6.6 Hz, 1 H), 4.60 (d, J=12.0 Hz, 1 H), 4.44-4.47 (m, 2 H), 4.42 (d, J=11.4 Hz, 1 H), 4.18 (dt, J=4.2, 7.2 Hz, 1 H), 3.54 (dd, J=4.2, 10.2 Hz, 1 H), 3.29 (dd, J=4.8, 10.8 Hz, 1 H), 2.83 ppm (brs, 1 H); ¹³C NMR (150 MHz, $CDCI_3$): $\delta = 184.9$ (d, 1 C), 159.5, 143.6, 137.4, 136.7, 128.6 (2 CH), 128.4 (2CH), 128.3, 128.1 (2CH), 127.9 (2CH), 127.8, 126.2, 108.2, 74.4, 73.6 (CH₂), 72.5, 72.1 (CH₂), 69.8 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max}$ = 1680 cm⁻¹; HRMS (ESI): m/z calcd for $C_{22}H_{22}O_5Na$ [*M*+Na]⁺: 389.1365; found: 389.1364.

3-Benzyloxy-2-benzyloxymethyl-5-ethynyl-2,3-dihydropyran-4-one (4pc)

Compound **3p** (0.05 g, 0.118 mmol) was converted to **4pb** (0.013 g, 30%) and **4pc** (0.014 g, 34%) by following the general procedure with PPh₃AuNTf₂ as catalyst. Similarly, **3p** (0.05 g, 0.118 mmol) was converted to **4pb** (0.014 g, 32%) and **4pc** (0.0075 g, 18%) by following the general procedure with PPh₃AuCl + AgOTf as catalyst. The analytical data of **4pb** were con-

sistent with the experimental details discussed above. Compound **4 pc**: eluent, EtOAc/*n*-hexane (12%); $[\alpha]_D^{20} = +14$ (c=0.1 in MeOH); white solid; m.p. 132 °C. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.75$ (s, 1 H), 7.27–7.36 (m, 10 H), 4.71 (d, J = 12.0 Hz, 1 H), 4.56 (d, J = 11.4 Hz, 1 H), 4.52–4.54 (m, 1 H), 4.49 (d, J = 11.4 Hz, 1 H), 4.46 (d, J = 12.0 Hz, 1 H), 3.91 (dd, J = 6.6, 10.2 Hz, 1 H), 3.79 (d, J = 1.8 Hz, 1 H), 3.76 (dd, J = 5.4, 10.2 Hz, 1 H), 3.07 ppm (s, 1 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 186.5$, 166.8, 137.3, 136.6, 128.5 (3CH), 128.4 (2CH), 128.4, 128.1, 128.0, 127.8 (2CH), 102.4, 81.3, 80.7, 74.4, 73.7 (CH₂), 73.3, 72.1 (CH₂), 67.2 ppm (CH₂); IR (KBr): $\tilde{\nu}_{max} = 3265$, 1693, 1586, 1198, 1102 cm⁻¹; HRMS (ESI): m/z calcd for $C_{22}H_{20}O_4$ Na $[M+Na]^+$: 371.1260; found: 371.1254.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)furan-3-carbaldehyde (4 pb)

Compound **4pc** (0.05 g, 0.143 mmol) was converted to **4pb** (0.025 g, 48%) by following the general procedure with PPh₃AuNTf₂ as catalyst. The analytical data of **4pb** were consistent with the experimental details discussed above: eluent, EtOAc/*n*-hexane (30%).

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-butylfuran-3-carbaldehyde (4 q)

Compound **3q** (0.05 g, 0.124 mmol) was converted to **4q** (0.027 g, 52%) by following the general procedure: eluent, EtOAc/*n*-hexane (20%); $[\alpha]_{20}^{20} = -22$ (c = 0.1 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 9.91$ (s, 1H), 7.21–7.34 (m, 10H), 6.33 (s, 1H), 4.91 (d, J = 7.2 Hz, 1H), 4.59 (d, J = 12.0 Hz, 1H), 4.41–4.46 (m, 3H), 4.17–4.18 (m, 1H), 3.53 (dd, J = 3.6, 10.2 Hz, 1H), 3.28 (dd, J = 4.2, 9.6 Hz, 1H), 2.85 (brs, 1H), 2.58–2.61 (m, 2H), 1.58–1.62 (m, 2H), 1.32–1.39 (m, 2H), 0.93 ppm (t, J = 7.8 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 185.0$, 158.3, 157.9, 137.5, 136.8, 128.6 (2CH), 128.4 (2CH), 128.2, 128.1 (2CH), 127.8 (2CH), 127.8, 127.1, 102.9, 74.3, 73.6 (CH₂), 72.5, 71.9 (CH₂), 69.8 (CH₂), 29.5 (CH₂), 27.3 (CH₂), 22.1 (CH₂), 13.7 ppm (CH₃); IR (KBr): $\tilde{\nu}_{max} = 1677$ cm⁻¹; HRMS (ESI): m/z calcd for C₂₆H₃₀O₅Na [M+Na]⁺: 445.1991; found: 445.1991.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-butylfuran-3-carbaldehyde (4 r)

Compound **3r** (0.05 g, 0.124 mmol) was converted to **4r** (0.027 g, 52%) by following the general procedure: eluent, EtOAc/*n*-hexane (20%); $[\alpha]_{0}^{20} = +1$ (c=0.1 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): δ = 9.91 (s, 1H), 7.21–7.36 (m, 10H), 6.36 (s, 1H), 4.82 (d, J=7.2 Hz, 1H), 4.49–4.55 (m, 3H), 4.36 (d, J=12.0 Hz, 1H), 4.19–4.23 (m, 1H), 3.69 (dd, J=5.4, 9.6 Hz, 1H), 3.65 (dd, J=3.6, 9.6 Hz, 1H), 2.63 (t, J=7.8 Hz, 2H), 2.47 (d, J=6.0 Hz, 1H), 1.60–1.65 (m, 2H), 1.36–1.39 (m, 2H), 0.93 ppm (t, J=7.2 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =186.2 (d, 1C), 159.7, 159.2, 138.6, 137.9, 129.5 (2CH), 129.5 (2CH), 129.1, 129.0 (2CH), 128.9, 128.8 (2CH), 128.5, 104.0, 74.5 (CH₂), 74.4 (CH₂), 72.6, 72.5 (CH₂), 71.3 (CH₂), 30.6 (CH₂), 28.4 (CH₂), 23.1 (CH₂), 14.8 ppm (CH₃); IR (KBr): $\tilde{\nu}_{max}$ = 1675 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₆H₃₀O₅Na [*M*+Na]⁺: 445.1991; found: 445.1987.

2-(1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-cyclopentylfuran-3carbaldehyde (4s)

Compound **3s** (0.05 g, 0.120 mmol) was converted to **4s** (0.043 g, 82%) by following the general procedure: eluent, EtOAc/*n*-hexane (20%); $[\alpha]_D^{20} = +66$ (c = 0.1 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 9.91$ (s, 1H), 7.20–7.37 (m, 10H), 6.36 (s, 1H),

Chem. Eur. J. **2014**, 20, 1–15

www.chemeurj.org



CHEMISTRY A European Journal Full Paper

4.82 (d, J=7.2 Hz, 1H), 4.48–4.56 (m, 3 H), 4.37 (d, J=11.7 Hz, 1 H), 4.22 (m, 1H), 3.62–3.71 (m, 2H), 3.08 (quin, J=7.2 Hz, 1 H), 2.50 (d, J=4.5 Hz, 1 H), 2.00–2.50 (m, 2 H), 1.50–1.74 ppm (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ =185.3, 161.6, 158.7, 137.6, 137.0, 128.5 (2 CH), 128.5 (2 CH), 128.1 (2 CH), 128.0, 127.9, 127.8 (2 CH), 127.3, 101.6, 73.7, 73.5 (CH₂), 71.6 (CH₂), 71.6, 70.3 (CH₂), 38.3, 31.6 (CH₂), 31.5 (CH₂), 25.1 ppm (2 CH₂); IR (KBr): $\tilde{\nu}_{max}$ =1676 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₇H₃₀O₅Na [*M*+Na]⁺: 457.1991; found: 457.2024.

6-(*tert*-Butyldimethylsilanyloxymethyl)-4-methoxy-2-phenyl-6,7-dihydro-4*H*-furo[3,2-c]pyran-7-ol (5 a)

AuCl₃ (0.0127 g, 10 mol%) and then methanol (0.034 mL, 2 equiv) were added to a well-stirred solution of 3c (0.150 g, 0.418 mmol) in dry THF (2.5 mL) under an argon atmosphere. The resulting reaction mixture was stirred at room temperature for 20 min. After completion of the reaction (TLC), the solvent was removed under reduced pressure, and the residue was purified by flash chromatography on silica gel (230-400) to obtain compound 5a (0.089 g, 55%): eluent: EtOAc/n-hexane (7.5%); white solid; m.p. 120°C. ¹H NMR (300 MHz, CDCl₃): δ = 7.67 (d, J = 7.2 Hz, 2 H), 7.35–7.40 (m, 2H), 7.26-7.30 (m, 1H), 6.60 (s, 1H), 5.53 (s, 1H), 4.65 (dd, J=1.5, 6.9 Hz, 1 H), 4.20-4.25 (m, 1 H), 3.97-4.04 (m, 2 H), 3.54 (s, 3 H), 2.42 (d, J=7.5 Hz, 1 H), 0.93 (s, 9 H), 0.13 ppm (d, J=2.4 Hz, 6 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 154.8$, 150.3, 130.3, 128.7 (2 CH), 127.9, 124.1 (2CH), 121.4, 102.5, 95.9, 71.7, 62.4 (CH₂), 61.8, 55.7, 25.9 (3CH₃), 18.2, -5.4 ppm (2CH₃); HRMS (ESI): m/z calcd for C₂₁H₃₀O₅SiNa [*M*+Na]⁺: 413.1761; found: 413.1755.

7-Benzyloxy-6-benzyloxymethyl-2-phenyl-6,7-dihydrofuro-[3,2-c]pyran-4-one (5 b)

PDC (0.127 g, 0.339 mmol, 3 equiv) was added to a well-stirred solution of 4a (0.05 g, 0.113 mmol) in dry dichloromethane (5 mL) under an argon atmosphere. The resulting reaction mixture was stirred at room temperature for 48 h. After completion of reaction (TLC), saturated NaHCO₃ solution was added, and the product was extracted with CH2Cl2. The combined organic layers were dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to get a crude residue. The residue was purified by using silica gel column chromatography to obtain **5 b** (0.020 g, 40%): eluent: EtOAc/*n*-hexane (20%); $[\alpha]_{D}^{20} = +48$ (*c* = 0.1 in MeOH); white solid; m.p. 74°C. ¹H NMR (600 MHz, CDCl₃): δ = 7.67–7.68 (m, 2H), 7.43–7.45 (m, 2H), 7.25–7.38 (m, 9H), 7.21– 7.22 (m, 2H), 6.94 (s, 1H), 5.00 (d, J=4.2 Hz, 1H), 4.85-4.87 (m, 2H), 4.73 (d, J=11.4 Hz, 1H), 4.52 (d, J=11.4 Hz, 1H), 4.48 (d, J= 12.0 Hz, 1 H), 3.77 (dd, J=4.2, 10.2 Hz, 1 H), 3.63 ppm (dd, J=6.0, 10.8 Hz, 1 H); $^{13}{\rm C}$ NMR (150 MHz, CDCl_3): $\delta\!=\!$ 160.8, 158.1, 156.4, 137.3, 136.9, 129.1, 128.9 (2CH), 128.8, 128.6 (2CH), 128.4 (2CH), 128.2, 128.1 (2CH), 127.9, 127.6 (2CH), 124.3 (2CH), 114.9, 102.5, 81.5, 73.5 (CH₂), 72.2 (CH₂), 68.5 (CH₂), 67.0 ppm; IR (KBr): $\tilde{\nu}_{max} =$ 1745 cm⁻¹; HRMS (ESI): m/z calcd for $C_{28}H_{24}O_5Na$ [*M*+Na]⁺: 463.1522; found: 463.1192.

2-(3-Benzyloxy-2-oxopropyl)-5-phenylfuran-3-carbaldehyde (6)

TiBr₄ (0.083 g, 0.226 mmol, 2 equiv) was added to a well-stirred solution of **4a** or **4b** (0.05 g, 0.113 mmol) in dry toluene (2.5 mL) under an argon atmosphere. The resulting reaction mixture was heated under reflux conditions for 8 h. After completion of reaction (TLC), saturated NH₄Cl solution was added, and the product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄ and filtered, and the filtrate was concentrated under reduced pressure to get a crude residue. The residue was purified by using silica gel column chromatography to obtain **6** (0.016 g, 43%): eluent: EtOAc/*n*-hexane (15–20%); yellow gum. ¹H NMR (600 MHz, CDCl₃): δ = 9.91 (s, 1H), 7.64 (d, *J* = 7.2 Hz, 2H), 7.31–7.42 (m, 8H), 6.96 (s, 1H), 4.64 (s, 2H), 4.26 (s, 2H), 4.22 ppm (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ = 202.1, 185.2 (d, 1C), 154.8, 154.7, 136.7, 129.3, 128.8 (2CH), 128.6 (2CH), 128.4, 128.2, 128.0 (2CH), 125.7, 124.1 (2CH), 103.4, 74.9 (CH₂), 73.7 (CH₂), 38.4 ppm (CH₂); IR (KBr): \hat{v}_{max} = 1681, 1735 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₁H₁₈O₄Na [*M*+Na]⁺: 357.1103; found: 357.1106.

6-Benzyloxymethyl-2-phenylfuro[3,2-c]pyridine (7)

1,5-Dicarbonyl derivative 6 (0.022 g, 0.066 mmol) was dissolved in a solution of NH₄OAc (50.7 mg, 0.66 mmol, 10 equiv) and acetic acid (0.04 mL, 0.66 mmol, 10 equiv) in ethanol (0.01 M with respect to 6). The resulting mixture was heated at 40°C for 12 h. After completion of reaction (TLC), the reaction mixture was cooled to room temperature and diluted with ethyl acetate, washed with aqueous saturated NaHCO₃ solution, followed by brine solution. The combined organic layers were dried over anhydrous Na₂SO₄ and filtered, and the filtrate was concentrated under reduced pressure to get a crude residue. The crude residue was purified by using silica gel column chromatography to obtain 7 (0.012 g, 60%); eluent: EtOAc/n-hexane (35%); light yellow solid; m.p. 88 °C. ¹H NMR (600 MHz, CDCl₃): $\delta = 8.84$ (s, 1 H), 7.86–7.87 (m, 2 H), 7.68 (s, 1 H), 7.47 (t, J=7.2 Hz, 2 H), 7.36-7.43 (m, 5 H), 7.30-7.32 (m, 1 H), 7.05 (s, 1 H), 4.83 (s, 2 H), 4.70 ppm (s, 2 H); ¹³C NMR (150 MHz, $CDCl_3$): $\delta = 160.3$, 157.1, 153.9, 142.7, 138.0, 129.5, 129.3, 128.9 (2CH), 128.4 (2CH), 127.8 (2CH), 127.7, 125.5, 125.2 (2CH), 104.6, 99.0, 73.0 (CH₂), 72.9 ppm (CH₂); HRMS (ESI): m/z calcd for C₂₁H₁₈NO₂ [*M*+H]⁺: 316.1337; found: 316.1104.

Acknowledgements

I.D. thanks DST-SERB (no. SB/FT/CS-105/2012) for financial support, and Drs. Basudeb Achari and Ramalingam Natarajan for valuable discussions. K.M. thanks the CSIR, India for a fellow-ship. A.S. thanks NIPER-Kolkata for a fellowship. We thank the reviewers for their valuable comments and suggestions, which helped significantly to improve the quality of the manuscript.

Keywords: carbohydrates · chirality · furans · gold · homogeneous catalysis

- a) A. Boto, L. Alvarez in *Heterocycles in Natural Product Synthesis* (Eds.: K. C. Majumdar, S. K. Chattopadhyay), Wiley-VCH, Weinheim, Germany, **2011**, pp. 97–152; b) H. N. C. Wong, K.-S. Yeung, Z. Yang in *Comprehensive Heterocyclic Chemistry, Vol. 3* (Eds.: A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven, R. J. K. Taylor), Elsevier, Oxford, **2008**, pp. 408–496; c) X. L. Hou, Z. Yang, H. N. C. Wong in *Progress in Heterocyclic Chemistry, Vol. 15* (Eds.: G. W. Gribble, T. L. Gilchrist), Pergamon, Oxford, **2003**, pp. 167–205; d) H. Heaney, J. S. Ahn in *Comprehensive Heterocyclic Chemistry II, Vol. 2* (Eds.: A. R. Katritzky, C. W. Rees, E. F. V. Scriven), Elsevier, Oxford, **1997**, pp. 297–350.
- [2] For selected references, see: a) A. V. Gulevich, A. S. Dudnik, N. Chernyak, V. Gevorgyan, *Chem. Rev.* 2013, *113*, 3084–3213; b) E. B. Murphy, F. Wudl, *Prog. Polym. Sci.* 2010, *35*, 223–251; c) A. Gandini, A. J. D. Silvestre, C. P. Neto, A. F. Sousa, M. N. Gomes, *Polym. Chem.* 2009, *47*, 295–298; d) H.-C. Lin, W.-Y. Lin, H.-T. Bai, J.-H. Chen, B.-Y. Jin, T.-Y. Luh, *Angew. Chem.* 2007, *119*, 915–918; *Angew. Chem. Int. Ed.* 2007, *46*, 897–900; e) R. C. D. Brown, *Angew. Chem.* 2005, *117*, 872–874; *Angew. Chem. Int.*

Chem. Eur. J. **2014**, 20, 1 – 15

www.chemeurj.org

12

 $\ensuremath{^{\odot}}$ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim



Ed. **2005**, *44*, 850–852; f) M. D. Burke, E. M. Berger, S. L. Schreiber, *J. Am. Chem. Soc.* **2004**, *126*, 14095–14104.

ChemPubSoc Europe

- [3] For selected reviews, see: a) M. Rudolph, A. S. K. Hashmi, Chem. Soc. Rev. 2012, 41, 2448–2462; b) N. Krause, C. Winter, Chem. Rev. 2011, 111, 1994–2009; c) A. Corma, A. Leyva-Pérez, M. J. Sabater, Chem. Rev. 2011, 111, 1657–1712; d) A. S. K. Hashmi, Angew. Chem. 2010, 122, 5360–5369; Angew. Chem. Int. Ed. 2010, 49, 5232–5241; e) Z. Li, C. Brouwer, C. He, Chem. Rev. 2008, 108, 3239–3265; f) A. S. K. Hashmi, G. J. Hutchings, Angew. Chem. 2006, 118, 8064–8105; Angew. Chem. Int. Ed. 2006, 45, 7896–7936; g) G. Zeni, R. C. Larock, Chem. Rev. 2004, 104, 2285–2309; h) G. Balme, D. Bouyssi, T. Lomberget, N. Monteiro, Synthesis 2002, 6, 841–864; j) S. Cacchi, G. Fabrizi, A. Goggiomani, Heterocycles 2002, 56, 613–632; k) T. L. Gilchrist, J. Chem. Soc. Perkin Trans. 1 1999, 2849–2866.
- [4] a) E. A. Kazancioglu, M. Z. Kazancioglu, M. Fistikci, H. Secen, R. Altundas, Org. Lett. 2013, 15, 4790–4793; b) J. Robertson, P. T. Chovatia, T. G. Fowler, J. M. Withey, D. J. Woollaston, Org. Biomol. Chem. 2010, 8, 226– 233; c) J. A. Coral, H. Guo, M. Shan, G. A. O'Doherty, Heterocycles 2009, 79, 521–529; d) J. M. Harris, M. Li, J. G. Scott, G. A. O'Doherty in Achmatowicz Approach To 5,6-Dihydro-2H-Pyran-2-One Containing Natural Products in Strategy and Tactics in Natural Product Synthesis (Ed.: Michael Harmata), Elsevier, London, 2004.
- [5] For selected references, see: a) W. Wang, G. B. Hammond, B. Xu, J. Am. Chem. Soc. 2012, 134, 5697–5705; b) A. S. K. Hashmi, M. Rudolph, Chem. Soc. Rev. 2008, 37, 1766–1775; c) N. T. Patil, Y. Yamamoto, Chem. Rev. 2008, 108, 3395–3442; d) A. Arcadi, Chem. Rev. 2008, 108, 3266– 3325; e) H. C. Shen, Tetrahedron 2008, 64, 7847–7870; f) A. S. K. Hashmi, Chem. Rev. 2007, 107, 3180–3211; g) G. Kirsch, S. Hesse, A. Comel, Curr. Org. Synth. 2004, 1, 47–63; h) N. T. Patil, H. Wu, Y. Yamamoto, J. Org. Chem. 2005, 70, 4531–4534; i) T. Yao, X. Zhang, R. C. Larock, J. Org. Chem. 2005, 70, 7679–7685; j) C. H. Oh, V. R. Reddy, A. Kim, C. Y. Rhim, Tetrahedron Lett. 2006, 47, 5307–5310; k) X. Liu, Z. Pan, X. Shu, X. Duan, Y. Liang, Synlett 2006, 1962–1964.
- [6] a) B. Thirupathi, P. P. Reddy, D. K. Mohapatra, J. Org. Chem. 2011, 76, 9835–9840; b) S. F. Kirsch, Org. Biomol. Chem. 2006, 4, 2076–2080; c) H. Ila, O. Baron, A. J. Wagner, P. Knochel, Chem. Commun. 2006, 583–593; d) X. L. Hou, H. Y. Cheung, T. Y. Hon, P. L. Kwan, T. H. Lo, S. Y. Tong, H. N. C. Wong, Tetrahedron 1998, 54, 1955–2020.
- [7] a) P. Hara, M.-C. Turcu, R. Sundell, M. Tosa, C. Paizs, F.-D. Irimie, L. T. Kanerva, *Tetrahedron: Asymmetry* **2013**, *24*, 142–150; b) D. Noutsias, A. Kouridaki, G. Vassilikogiannakis, *Org. Lett.* **2011**, *13*, 1166–1169; c) K. Cheng, A. R. Kelly, R. A. Kohn, J. F. Dweck, P. J. Walsh, *Org. Lett.* **2009**, *11*, 2703–2706; d) M. Lombardo, S. Morganti, C. Trombini, *J. Org. Chem.* **2003**, *68*, 997–1006.
- [8] a) Ł. Albrecht, L. K. Ransborg, B. Gschwend, K. A. Jørgensen, J. Am. Chem. Soc. 2010, 132, 17886–17893; b) T. B. Poulsen, K. A. Jørgensen, Chem. Rev. 2008, 108, 2903–2915; c) J. Majer, P. Kwiatkowski, J. Jurczak, Org. Lett. 2008, 10, 2955–2958; d) P. Kwiatkowski, J. Majer, W. Chaładaj, J. Jurczak, Org. Lett. 2006, 8, 5045–5048; e) D. Uraguchi, K. Sorimachi, M. Teradaa, J. Am. Chem. Soc. 2004, 126, 11804–11805.
- [9] For recent selected references, see: a) J. Zhang, C. Xing, B. Tiwari, Y. R. Chi, J. Am. Chem. Soc. 2013, 135, 8113-8116; b) Z. Zhang, B. Du, L.-J. Zhang, Y.-X. Da, Z.-J. Quan, L.-J. Yanga, X.-C. Wang, RSC Adv. 2013, 3, 9201-9205; c) R. Cordonniera, A. Nguyen Van Nhiena, E. Sorianob, J. Marco-Contellesb, D. Postel, Tetrahedron 2010, 66, 736-742; d) M. Saguib, I. Husain, B. Kumar, A. K. Shaw, Chem. Eur. J. 2009, 15, 6041-6049; e) D. Mukherjee, S. K. Yousuf, S. C. Taneja, Org. Lett. 2008, 10, 4831-4834; f) A. Boto, D. Hernández, R. Hernández, Ora. Lett. 2007, 9, 1721 - 1724; g) G. Bartoli, J. G. Fernández-Bolaños, G. Di Antonio, G. Foglia, S. Giuli, R. Gunnella, M. Mancinelli, E. Marcantoni, M. Paoletti, J. Org. Chem. 2007, 72, 6029-6036; h) A. Agarwal, S. Rani, Y. D. Vankar, J. Org. Chem. 2004, 69, 6137-6140; i) B. Sobhana Babu, K. K. Balasubramanian, J. Org. Chem. 2000, 65, 4198-4199; j) D. R. Kelly, M. R. Picton, J. Chem. Soc. Perkin Trans. 1 2000, 1559-1569; k) M. Hayashi, H. Kawabata, K. Yamada, Chem. Commun. 1999, 965-966; I) S. F. Martin, P. W. Zinke, J. Org. Chem. 1991, 56, 6600-6606.
- [10] W. Zhang, P. G. Wang, J. Org. Chem. 2000, 65, 4732-4735.
- [11] Y. Kobayashi, M. Kusakabe, Y. Kitano, F. Sato, J. Org. Chem. 1988, 53, 1586–1587.

garapu, M. V. Chary, A. Satyender, B. Supriya, B. Rajashaker, *Synthesis* 2009, 2278–2282. (1, [13] A. R. Kelly, M. H. Kerrigan, P. J. Walsh, *J. Am. Chem. Soc.* 2008, 130,

4097-4104. [14] A. N. Butkevich, L. Meerpoel, I. Stansfield, P. Angibaud, A. Corbu, J. Cossy, *Org. Lett.* **2013**, *15*, 3840-3843.

[12] a) F. García González, Adv. Carbohydr. Chem. 1956, 11, 97-143; b) L. Na-

- [15] For recent selected references, see: a) J. Yang, C. Wang, X. Xie, H. Li, E. Li, Y. Li, Org. Biomol. Chem. 2011, 9, 1342–1346; b) P. Jakubec, D. M. Cockfield, D. J. Dixon, J. Am. Chem. Soc. 2009, 131, 16632–16633; c) A. D. Wright, R. D. Nys, C. K. Angerhofer, J. M. Pezzuto, M. Gurrath, J. Nat. Prod. 2006, 69, 1180–1187; d) S. N. Patil, F. Liu, Org. Lett. 2007, 9, 195–198; e) A. Husain, M. S. Y. Khan, S. M. Hasan, M. M. Alam, Eur. J. Med. Chem. 2005, 40, 1394–1404; f) M. Braun, A. Hohmann, J. Rahematpura, C. Buehne, S. Grimme, Chem. Eur. J. 2004, 10, 4584–4593; g) J. Kobayashi, M. Tsuda, M. Ishibashi, Pure Appl. Chem. 1999, 71, 1123–1126; h) J. Kobayashi, D. Watanabe, N. Kawasaki, M. Tsuda, J. Org. Chem. 1997, 62, 9236–9239.
- [16] a) B. A. Keay, Chem. Soc. Rev. **1999**, 28, 209–215; b) G. Raffa, G. Balme, N. Monteiro, Eur. J. Org. Chem. **2013**, 105–110; c) T. Wang, S. Shi, M. M. Hansmann, E. Rettenmeier, M. Rudolph, A. S. K. Hashmi, Angew. Chem. **2014**, 126, 3789–3793; Angew. Chem. Int. Ed. **2014**, 53, 3715–3719, and references therein.
- [17] a) P. S. Bailey, J. V. Waggoner, G. Nowlin, G. L. Rushton, J. Am. Chem. Soc. 1954, 76, 2249–2251; b) K. Hiroya, K. Ogasawara, Synlett 1995, 175– 176.
- [18] F. Leonelli, M. Capuzzi, V. Calcagno, P. Passacantilli, G. Piancatelli, Eur. J. Org. Chem. 2005, 2671–2676.
- [19] a) T. E. Goodwin, C. M. Crowder, R. B. White, J. S. Swanson, F. E. Evans, W. L. Meyer, J. Org. Chem. 1983, 48, 376–380; b) A. Kirschning, J. Org. Chem. 1995, 60, 1228–1232; c) A. Kirschning, U. Hary, C. Plumeier, M. Ries, L. Rose, J. Chem. Soc. Perkin Trans. 1 1999, 519–528; d) H.-G. Weinig, P. Passacantilli, M. Colapietro, G. Piancatelli, Tetrahedron Lett. 2002, 43, 4613–4615; e) D. Ganguly, H. Tang, M. J. Rodriguez, Synth. Commun. 2007, 37, 4219–4226.
- [20] a) C.-H. Cho, F. Shi, D.-I. Jung, B. Neuenswander, G. H. Lushington, R. C. Larock, ACS Comb. Sci. 2012, 14, 403–414; b) D. C. Koester, D. B. Werz, Beilstein J. Org. Chem. 2012, 8, 675–682; c) R. Chinchilla, C. Najera, Chem. Soc. Rev. 2011, 40, 5084–5121.
- [21] a) A. S. K. Hashmi, F. Ata, P. Haufe, F. Rominger, *Tetrahedron* 2009, *65*, 1919–1927; b) A. S. K. Hashmi, J. Hofmann, S. Shi, A. Schütz, M. Rudolph, C. Lothschütz, M. Wieteck, M. Bührle, M. Wölfle, F. Rominger, *Chem. Eur. J.* 2013, *19*, 382–389.
- [22] a) W. Reppe, Justus Liebigs Ann. Chem. 1956, 601, 81–138; b) One of the reviewers suggested to examine more reactive cationic gold(I) catalyst in these cyclization reactions: c) N. Mézailles, L. Ricard, F. Gagosz, Org. Lett. 2005, 7, 4133–4136.
- [23] a) T. Yao, X. Zhang, R. C. Larock, J. Am. Chem. Soc. 2004, 126, 11164–11165; b) G. Cheng, Y. Hu, Chem. Commun. 2007, 3285–3287; c) L. Huang, F. Hu, Q. Ma, Y. Hu, Tetrahedron Lett. 2013, 54, 3410–3414.
- [24] A. S. Dudnik, Y. Xia, Y. Li, V. Gevorgyan, J. Am. Chem. Soc. 2010, 132, 7645-7655.
- [25] The details with other nucleophiles will be reported in due course.
- [26] G. J. McGarvey, C. A. LeClair, B. A. Schmidtmann, Org. Lett. 2008, 10, 4727-4730.
- [27] For some recent examples, see: a) G. Hatzivassiliou, J. R. Haling, H. Chen, K. Song, S. Price, R. Heald, J. F. M. Hewitt, M. Zak, A. Peck, C. Orr, M. Merchant, K. P. Hoeflich, J. Chan, S.-M. Luoh, D. J. Anderson, M. J. C. Ludlam, C. Wiesmann, M. Ultsch, L. S. Friedman, S. Malek, M. Belvin, *Nature* 2013, *501*, 232–236; b) K. Eis, F. Puhler, L. Zorn, A. Scholz, P. Lienau, M. Jean Gnoth, U. Bomer, J. Gunther, (Bayer IP GMBH), WO 2013041634 A1 2013; c) X. Zheng, P. Bauer, T. Baumeiste, A. J. Buckmelter, M. Caligiuri, K. H. Clodfelter, B. Han, Y.-C. Ho, N. Kley, J. Lin, D. J. Reynolds, G. Sharma, C. C. Smith, Z. Wang, P. S. Dragovich, J. Gunzner-Toste, B. M. Liederer, J. Ly, T. O'Brien, A. Oh, L. Wang, W. Wang, Y. Xiao, M. Zak, G. Zhao, P.-W. Yuen, K. W. Bair, *J. Med. Chem.* 2013, *56*, 6413–6433; d) P. E. Chabrier, P. Guinot, T. Tarrade, M. Auguet, M. Cabanie, F. Clostre, A. Etienne, A. Esanu, P. Braquet, *Cardiovasc. Drug Rev.* 1988, *6*, 166–179.
- [28] For some recent examples, see: a) L. I. Dixon, M. A. Carroll, T. J. Gregson, G. J. Ellames, R. W. Harrington, W. Clegg, *Eur. J. Org. Chem.* 2013, 2334– 2345; b) J.-G. Xiang, W.-G. Shan, D.-E. Liang, Y.-M. Ying, L.-S. Gan, J.-W.

Chem. Eur. J. **2014**, 20, 1–15

www.chemeurj.org

13

© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim



Wang, Z.-J. Zhan, *Helv. Chim. Acta* **2013**, *96*, 997–1003; c) N. S. L. Rao, M. V. B. Rao, *Chem. J.* **2013**, *3*, 23–29; d) N. S. L. Rao, K. R. S. Prasada, M. V. B. Rao, *Chem. Sin.* **2013**, *4*, 17–23; e) D. Tarabová, J. Titiš, N. Prónayová, A. Gatial, A. Krutošíková, *ARKIVOC* **2010**, *2010*, 269–281; f) W. S. Yue, J. J. Li, *Org. Lett.* **2002**, *4*, 2201–2203; g) S. Yamaguchi, E. Hamade, H. Yokoyama, Y. Hirai, S. Shiotani, *J. Heterocycl. Chem.* **2002**, *39*, 335– 339. [29] a) T. J. Donohoe, J. A. Basutto, J. F. Bower, A. Rathi, *Org. Lett.* 2011, *13*, 1036–1039; b) S. Tokuji, Y. Takahashi, H. Shinmori, H. Shinokubo, A. Osuka, *Chem. Commun.* 2009, 1028–1030.

[30] L. I. Palmer, J. R. de Alaniz, Org. Lett. 2013, 15, 476-479.

Received: February 21, 2014 Published online on ■■ ■, 0000



FULL PAPER



Golden energy! An efficient gold(III)catalyzed route to substituted chiral 3formyl furans under extremely mild conditions from suitably protected 5-(1-alkynyl)-2,3-dihydropyran-4-ones and H₂O as a nucleophile is described (see

[a] AuCl₃, H₂O, THF RT, 5-10 min yield up to 96% 19 examples

R¹ = H, Me, CH₂OBn, CH₂OTBS R² = OBn, OH R³ = aromatic, aliphatic, TMS, H

scheme, TBS = *tert*-butyldimethylsilyl). The latter can easily be synthesized from appropriately functionalized monosaccharides or commercially available glycals in a few steps.

Chiral Furans

K. Mal, A. Sharma, I. Das*



Gold(III) Chloride Catalyzed Synthesis of Chiral Substituted 3-Formyl Furans from Carbohydrates: Application in the Synthesis of 1,5-Dicarbonyl Derivatives and Furo[3,2-c]pyridine

CHEMISTRY A European Journal

Full Paper